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 Priming, in the context of nonviral gene delivery, is the treatment of cells with a 
compound prior to gene transfer that enhances transfection efficiency and/or transgene 
expression.  Essentially, it is the application of an adjuvant approach to gene delivery.  
Effective transfection strategies may require priming to compete with the efficiency of 
viral transduction in order to achieve clinically relevant efficiency and expression in vivo.  
To search for priming compounds, a high throughput screen of the NIH Clinical 
Collection was performed using 25kDa b-PEI, an EGFP/luciferase plasmid, and 
HEK293T cells.  The EGFP reporter was multiplexed with Hoechst 33342 and Resazurin 
fluorescence to measure transfection efficiency, transgene expression, proliferation, and 
viability of the cells in response to priming with the screened NCC compounds and PEI 
transfection.  The screen identified dozens of compounds and several compound classes 
that appear to affect transfection through modulation of mitochondrial dysfunction in 
response to the toxicity of PEI complexes.  With further investigation and development, 
the mechanisms by which these and other priming compounds are affecting gene transfer 
can be understood and applied towards the development of efficient gene delivery 
strategies.
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CHAPTER 1 
Pharmacological Priming, High Throughput Screening, and Drug Repurposing, in 
the Context of Nonviral Gene Delivery 
 
1.1 Introduction 
 
The purpose of this chapter is to provide context for the research performed for 
this thesis.  After a brief introduction to the various methods of gene delivery, the 
primary barriers to successful nonviral gene delivery are presented.  A literature review 
follows, which covers nucleic acid and cationic polymer design for transfection, 
pharmacological priming to enhance transfection, high throughput screening methods in 
general and in the context of gene delivery, and drug repurposing considerations in the 
search for new priming compounds. 
 
1.2 Gene delivery 
 
Gene delivery is the transfer of exogenous nucleic acids into cells to modify 
cellular gene expression. Modulation of gene expression is useful for studying biological 
mechanisms which genes control, and can potentially enable gene therapies for treatment 
of genetic disorders.  There are countless applications in medical research that depend on 
the expression or silence of genes, and gene delivery methods are the tools which must be 
developed to achieve these functions inside target cells.  
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 Sickle-cell anemia is an example of a genetic disorder which can possibly be 
treated by gene delivery [1-3]. In sickle-cell anemia, abnormal red blood cell morphology 
is caused by mutation to the beta chain structure of hemoglobin, causing hemoglobin 
polymerization.  Correcting this mutation by gene therapy might be possible in different 
ways.  One therapy might involve delivering a combination of RNA interference and 
DNA plasmid encoding correct hemoglobin to hematopoietic stem cells (HSCs) for 
simultaneous knockdown of faulty hemoglobin expression and expression of functional 
hemoglobin.  Other methods might involve the correction (excision and replacement) of 
the faulty gene in vitro of harvested autologous HSCs for re-implantation, or perhaps 
involve targeted genome editing of HSCs in vivo.  These gene therapies would all require 
safe and effective gene delivery.  Towards this end, various methods of gene delivery 
have been extensively investigated. 
 
1.2.1 Viral gene delivery 
 
Gene delivery can be broadly classified into viral and nonviral methods.  Viral 
methods employ viral vectors for gene transfer, while nonviral methods accomplish gene 
delivery by physical or chemical means.  Viruses naturally transfer their genome into host 
cells for replication, a process which can be adapted for exogenous gene transfer [4] by 
insertion of the transgene into the viral genome.  The viral vector then facilitates the gene 
transfer into cells, a process referred to as transduction.  Transduction is highly efficient 
in vitro and in vivo, however, it is not trivial to modify a virus to deliver a specific gene 
of interest to target cells [5], and transduction is limited by design constraints and safety 
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concerns, a few of which include: size of the transgene [6], host immune response [7], 
and insertional mutagenesis [8].  Insertional mutagenesis is a risk for viral methods such 
as adeno-associated viral vectors, which integrate their genomes into the host genome.  
Transgene length is also a design constraint for many vectors, for instance, adeno-
associated vectors are limited to a transgene capacity of around 4.8kb.  Also, the host 
immune response to transduction can be potentially harmful to the host, and can decrease 
gene transfer efficiency in initial or repeated dosing as the host develops immunity to the 
viral vector [9].  Research is ongoing to develop viral vectors which overcome design 
constraints and decrease safety risks, however poor results in clinical trials (including 
subject fatality [10]) have prevented viral gene delivery from being utilized clinically.  
Even with limitations and concerns, viral gene delivery remains the gold standard for 
gene transfer efficiency against which all other gene delivery methods are measured. 
 
1.2.2 Nonviral gene delivery 
 
To surmount issues associated with viral gene delivery, nonviral methods of gene 
delivery have been developed.  Physical methods of nonviral gene delivery can be 
employed which internalize the transgene into cells past the cell membrane.  Bypassing 
the cell membrane can be accomplished by physical methods which include 
electroporation, magnetofection, ballistic insertion, ultrasound, and hydrodynamic 
delivery [6].  Electroporation and ultrasound disrupt the cell membrane allowing for 
nucleic acids to enter the cell, while ballistic and magnetofection methods use accelerated 
particles or magnetic nanoparticles to force nucleic acids into cells.  Hydrodynamic 
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delivery is the highest efficiency nonviral gene delivery method [6], which involves rapid 
injection of a large volume of fluid containing the nucleic acid into blood vessels.  This 
injection causes a transient high pressure in the local vasculature which disrupts capillary 
walls and cell membranes, allowing the nucleic acids to enter parenchyma cells 
surrounding the capillaries [11].  While many applications for these and other physical 
methods have been developed in vitro and in vivo, clinical applications of physical 
methods of gene transfer are limited because the physical disruption of cell membranes 
can be damaging, and targeting gene delivery to deep tissue with these methods requires 
invasive measures to provide direct access. 
Chemical methods of nonviral gene delivery do not rely on physical disruption of 
the cell membrane.  Instead, certain chemical compounds are able to associate with 
nucleic acids to form nanoparticles that facilitate the gene transfer into cells.  For human 
and mammalian cells, this chemical nonviral gene delivery is referred to as transfection.  
Transfection compounds are generally cationic, allowing them to condense the negatively 
charged nucleic acid into nanoparticle complexes which can associate with cell 
membranes and be internalized by endocytosis [6]. There are several types of cationic 
materials, referred to as carriers, which can associate with nucleic acids to achieve gene 
delivery, including various natural and synthetic lipids and polymers.  These materials 
can offer advantages over physical and viral methods of nonviral gene delivery, in safety, 
cost, fabrication, and flexibility in design and application.  For instance nonviral carriers 
are not necessarily limited like viral vectors by size of the transgene cargo or inherent 
immunogenicity of the viral capsid.  However, compared to viral methods, chemical 
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methods of nonviral gene delivery all suffer from lower transfection efficiency, especially 
in vivo [12]. 
 
1.2.3 Barriers to nonviral gene delivery 
 
There are many barriers to successful transfection, with each step contributing to 
the overall low efficiency of chemical methods of nonviral gene delivery.  Systemic 
barriers include serum stability, clearance, and targeting [13].  Serum stability refers to 
the ability of carrier nanoparticles to protect nucleic acids from degradation by nucleases 
in blood serum, avoid dissociation in serum buffer conditions, and avoid aggregation with 
other complexes or serum proteins. Clearance refers to the natural removal of exogenous 
material by the body, by macrophages [14] and through renal and hepatic filtration [15].  
Targeting is required to specifically transfect the cells which require the gene transfer, as 
non-specific transfection will decrease transfection efficiency at the target cells and could 
have unintended consequences.  
At the cellular level, the barriers to efficient transfection include internalization, 
endosomal escape, nuclear transport, nuclear import, and transcriptional and translational 
regulation [13] (illustrated in Figure 1.1 below). The carrier complexes need to be able to 
associate with the cell membrane and be internalized by various endocytosis pathways in 
order to enter the cell.  The complexes then need to escape the endosome to avoid 
degradation in a lysosome.  Escape into the cytosol followed by unpacking of the 
complexes is sufficient for RNA delivery, as RNA function is achieved in the cytoplasm, 
though nucleases in the cytoplasm will degrade the delivered RNA.  Transgenes encoded 
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into DNA require transport into the nucleus for the DNA to be transcribed for 
downstream expression through translation of mRNA to protein and protein folding.  
However, diffusion is not sufficient to carry the DNA through the cytoplasm to and into 
the nucleus, requiring active transport and import mechanisms [16].  At each step in the 
gene delivery process, there is enzymatic degradation of the delivered nucleic acids.  The 
rate limiting barriers and degradation in the transfection process combine to result in the 
overall low efficiency of chemical methods of nonviral gene delivery. 
 
 
Figure 1.1 Illustration of the cellular barriers to chemical nonviral gene delivery: 
internalization, endosomal escape, nuclear transport and import, and transcriptional and 
translational regulation. 
 
 
1.3 Nucleic acid design for nonviral gene delivery 
 
 The exogenous nucleic acids delivered to cells can be designed and modified to 
improve the gene transfer efficiency and effectiveness of the gene expression or 
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silencing.  Certain properties can be tuned to increase their effectiveness while other 
properties can be optimized to aid in overcoming cellular barriers.  The tunable design 
parameters depend on the intended application, with the nucleic acid being single or 
double stranded DNA or RNA.  For gene silencing, interfering RNAs or oligonucleotides 
are used, while for transgene expression, plasmid DNAs is suitable.   
Targeted reduction in expression of a gene can be accomplished through RNA 
interference (RNAi) or oligonucleotides.  Oligonucleotides are single stranded nucleic 
acids that can bind complementary mRNA sequences and prevent their expression 
through degradation by RNase H or steric blocking of translation [17], while RNAi 
involves short sequences of RNA which bind and degrade target mRNA through the 
RNA-induced silencing complexes (RISCs) [17].  It is thought that endogenous RNAi 
plays roles in both gene regulation and in defense against viruses and transposons [18]. 
The interfering RNA in RNAi are generally approximately twenty base pairs in length, 
double stranded in the case of small interfering RNA (siRNA) or single stranded in the 
case of micro-RNA (miRNA) [17-19].   Beyond internalization and endosomal escape, 
the primary determinants of gene silencing effectiveness by oligonucleotides and RNAi 
are the specific nucleic acid sequence and the delivered nucleic acid’s degradation rate, 
for which chemical modifications can be made to enhance their silencing activity and 
specificity, and improve nuclease degradation resistance [17, 19]. 
An advantage of RNAi and oligonucleotide nucleic acid delivery for gene 
silencing over nucleic acid delivery for transgene expression is that RNAi and 
oligonucleotides do not require translocation through the crowded cytoplasm to the 
nucleus and nuclear import, as plasmid DNA (pDNA) does.  These requirements are 
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additional barriers to efficient transfection that must be overcome to achieve successful 
transgene expression.  After endosomal escape, pDNA can remain complexed or unpack 
from the nanoparticles.  Depending on the carrier material, both packed and unpacked 
pDNA have been observed in the nuclei of transfected cells [20].  The transport of pDNA 
to the nucleus is not by passive diffusion, but through active transport along cytoskeletal 
elements [21, 22].   
Size and sequence of the pDNA influence the rate of transport and import into the 
nucleus, degradation, and transgene expression.  Size of the pDNA has been shown to 
affect overall transfection efficiency and transgene expression, with pDNA of shorter 
length being more effective, however it is uncertain whether this is due to more efficient 
nuclear transport and import [23].  pDNA sequence has also been shown to affect coiling 
structure of the nucleic acid, with supercoiled pDNA being optimum for transfection 
[23].  Bacterial elements in the pDNA sequence can also cause an immune response 
within the cell.  For instance, un-methylated CPG sequences are common in bacterial 
genomes, but not in mammalian DNA [24].  Toll-like receptors (TLRs) recognize 
bacterial elements like CPG sequences in pDNA and evoke an immune response at the 
cellular level that prevents sustained transgene expression by silencing of the transgene 
on the pDNA or elimination of the transfected cell [24].  To avoid this, CPG sequences 
can be minimized in plasmid design either by removal or methylation.  For instance, 
“minicircles”, plasmids which don’t contain a bacterial origin or antibiotic resistance 
cassettes, can be used to remove all bacterial elements from the plasmid for more 
sustained expression of the transgene [24].   
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pDNA sequence has also been shown to influence the rate of active transport to 
the nucleus and nuclear import.  Transcription factor binding sites on pDNA promoter 
and enhancer regions have been implicated in protein-DNA interactions, between 
transcription factors and pDNA, that shuttle pDNA within the cytoplasm along 
microtubules [16].  The nucleotide sequences that bind pDNA to transcription factors for 
transport are referred to as DNA targeting sequences (DTS) [16].  Transcription factors 
which translocate to the nucleus from the cytoplasm have nuclear localization signals 
(NLS) in their peptide sequence that facilitate import of transcription factors into the 
nucleus by importin proteins through Ran nuclear transport protein and the nuclear pore 
complex [16].  This nuclear import of transcription factors that possess NLS and are 
capable of binding pDNA at DTS may be the means by which pDNA enter the nucleus.  
Both cytomegalovirus (CMV) promoter and simian virus 40 (SV40) enhancer regions are 
known DTS that are commonly incorporated into plasmid designs and mediate nuclear 
transport and import through transcription factor binding in the cytoplasm followed by 
active transport along microtubules to the nucleus [16].  Though strong promoter regions 
in pDNA can compensate for low nuclear plasmid count [25], rendering optimizations of 
pDNA of limited value in vitro, low internalization rates in vivo will require such 
optimization in any nonviral gene delivery strategy which hopes to match viral 
transduction efficiencies and achieve sustained transgene expression. 
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1.4 Polyethylenimine carrier design in nonviral gene delivery 
 
 In addition to the properties of the nucleic acid cargo which generally determine 
the efficiency of a transfection strategy after endosomal escape, carrier properties and 
optimization are the most important determinants in the efficiency of a chemical nonviral 
gene delivery strategy in terms of facilitating delivery to and into cells.  Nonviral gene 
delivery with cationic polymers was first demonstrated with polylysine (PLL) in 1987 
[6], whose structure is illustrated in Figure 1.2 below. Its cationic nature allowed for the 
condensation of nucleic acids into nanoparticles which achieve gene delivery at low 
efficiency [26]. 
 
Figure 1.2  Polylysine (PLL) [27] 
 
 
The discovery of transfection with polyethylenimine (PEI), another cationic polymer, 
followed in 1995, with PEI demonstrating the ability to successfully transfect in vitro and 
in vivo in multiple cell types [28].  The chemical structure of the PEI polymer is shown in 
Figure 1.3 below. 
Cationic PEI also forms complexes with nucleic acids by electrostatic 
interactions, condensing with nucleic acids to form nanoparticles.  PEI nanoparticles 
protect nucleic acids from degradation by nucleases and facilitate gene transfer into cells.  
In contrast with PLL, PEI has a higher cationic charge density that enables more efficient 
transfection, though at the cost of increased toxicity [6]. 
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Figure 1.3  Polyethylenimine (PEI) [29] 
 
 
PEI chains have an amine group every three atoms along the polymer chain, with 
two carbon spacing between amine groups.  Substitution of secondary amines with 
tertiary amine groups in a PEI chain will introduce branching into to the polymer 
structure.   The cationic nature of PEI arises from the protonation of the densely packed 
secondary and tertiary amine groups in aqueous conditions, as amine groups are weak 
bases.  These positively charged ammonium groups are able to electrostatically associate 
with negatively charged nucleic acids to form the transfection competent nanoparticle 
complexes.   
The cationic nature of PEI not only condenses nucleic acids into nanoparticles for 
protection, but also allows for association of nucleic acids with the cell membrane.  
Nucleic acids are negatively charged due to their phosphate groups, which are naturally 
electrostatically repelled from the negative charge of the phosphate groups in the 
phospholipid bilayer of the cell membrane.  In order to enter the cell, the negative charge 
of nucleic acids must be neutralized.  Cationic PEI not only neutralizes the electrostatic 
repulsion of nucleic acids with the cell membrane, the net charge of PEI complexes is 
positive, achieving electrostatic attraction to the cell membrane, allowing PEI complexes 
to associate with the cell membrane for endocytosis. 
Endocytosis of PEI complexes occurs through clathrin and/or caveolar pathways, 
depending on cell type, and differing between branched and linear PEI variants [30].  
12 
 
Syndecan-dependent transport mechanisms involving filopodia have also been implicated 
in the cell membrane association and internalization process of nanoparticle complexes 
[31].  Endocytosis results in invagination of complexes which have associated with the 
cell membrane into the cell, in vesicles called endosomes.  PEI is able to escape 
endosomes at a higher rate than PLL (PLL designs often incorporate modification to 
include moieties such as chloroquine to enhance endosomal escape [12]), for reasons 
which again relate to the high density of amine groups in the PEI structure.  The exact 
mechanisms of PEI endosomal escape are still debated, as it is difficult to definitively 
observe events which occur in endosomes, but the combination of osmotic swelling of the 
endosome from the “proton sponge” effect, polymer swelling, and polymer endosomal 
membrane association and disruption, are thought to be involved [32].   
The proton sponge effect is explained by the increased affinity for protons of the 
amine groups in PEI under acidic conditions.  Endosomal pH is approximately 5, which 
increases the protonation degree of PEI to 40%, versus 20% at normal physiological 
buffered pH of 7.4 [33].  The high proton affinity of PEI in the endosome causes an 
influx of protons into the endosome, leading to an influx of chloride ions as well.  The 
overall influx of ions into the endosome causes an osmotic pressure which swells the 
endosome, contributing to its rupture [32].  In addition to the proton sponge effect, the 
increasingly protonated PEI experiences more and more electrostatic repulsion between 
its own ammonium groups, which leads to swelling of the polymer volume that  also 
disrupts the endosome membrane [32].  The highly protonated and positively charged 
PEI complexes also associate with the negatively charged endosome membrane causing 
further disruption [34].  The combination of proton sponge endosome swelling, polymer 
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swelling, and electrostatic interaction with the endosome membrane results in rupture of 
the endosome which allows PEI complexes to escape into the cytosol.   After endosomal 
escape, pDNA unpacking decreases the impact of PEI properties on the remaining steps 
in the transfection process, with the properties of the pDNA becoming the predominant 
determinants of subsequent successful transgene expression, though, some intact 
complexes have been observed localized in the nucleus [20], and PEI can have toxic 
effects in the cell [35]. 
  
1.4.1 Inefficiency and toxicity of PEI transfection 
 
 General optimization of PEI transfection is accomplished through tuning of the 
N/P ratio.  N/P is the ratio of amine groups in the PEI polymer to phosphate groups in the 
nucleic acid, determining the overall size and charge of the nanoparticle complexes.  The 
size and charge properties of these PEI nucleic acid complexes are the primary 
determinants of their ability to circulate in serum, be internalized into the cell, and escape 
the endosome, and thus are the primary determinants of transfection efficiency [28, 32, 
36].  It should be noted that higher N/P ratios have been shown to add free PEI that do 
not contribute to nanoparticle formation and instead remain free [37].  This free PEI has 
been shown to enhance overall transfection efficiency, for unknown reasons.  Optimized 
PEI transfection achieves efficiency of 50-80% in vitro depending on cell type [32], type 
of PEI, plasmid, and cell type, compared to the 100% efficiency achieved by optimized 
viral transduction in vitro [38].   
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PEI transfection efficiency of 50-80% in vitro could possibly translate to 
clinically relevant transfection efficiency in vivo if systemic barriers to transfection in 
vivo can be minimized and sustained transgene expression achieved [12].  PEI can be 
functionalized with ligands that allow for targeting of specific cell types through, ligand-
receptor binding, in order to increase effective transfection efficiency in vivo [32]. PEI 
can also be modified with polyethylene glycol (PEG) or other moieties to form a 
hydrophilic corona around the core PEI-nucleic acid nanoparticle, decreasing toxicity and 
improving degradation resistance by shielding the complexes from interacting with 
proteins, enzymes, and macrophages, increasing circulation time of the complexes in vivo 
[32].  However, PEGylation has been shown to decrease the ability of complexes to 
associate with cells and affect both the association and unpacking of the nucleic acid and 
the carrier, reducing overall transfection efficiency, so improvements in circulation and 
degradation resistance through PEGylation are achieved at a cost [32].  Bioresponsive 
linkages of PEG in transfection complexes are being investigated as a strategy to employ 
PEGylation while retaining optimized transfection efficiency, through shedding of the 
PEG shield at the cell membrane, in the endosome, or in the cytoplasm [34]. 
 Another tradeoff in PEI design relates to its toxicity.  PEI has been shown to 
cause mitochondrial dysfunction through disruption of the mitochondrial membrane that 
can result in oxidative stress and apoptosis [39].  Paradoxically, PEI designs which are 
more effectively able to overcome barriers to transfection also tend to be more toxic to 
the transfected cell.  For instance, high molecular weight (MW) and branched PEI 
complexes have been demonstrated to transfect at higher efficiencies compared to low 
MW and linear PEI complexes [40, 41], but also exhibit higher toxicity.  Attempts to 
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resolve this dilemma include bioresponsive linkages of low MW PEI into higher MW 
PEI-based polymers that will degrade in the cell into less toxic lower MW constituents 
[40]. 
 In the context of gene therapy clinical trials up to the year 2012, PEI and cationic 
polymer strategies in general have not been highly utilized in comparison to viral vectors 
and physical methods of naked DNA delivery [42].  Viral vectors achieve the highest 
targeted sustained gene transfer efficiency in vivo while naked DNA methods are less 
efficient and effective, yet arguably have the best and most predictable safety profile.  
Nonviral gene delivery strategies continue to be improved, but need to demonstrate 
improved efficiency and safety profiles that are competitive with or exceed both viral and 
physical methods of naked DNA gene delivery, respectively, to warrant vetting in clinical 
trials. 
 
1.5 Pharmacological priming as a tool for enhancing transfection 
 
Constraints on carrier and nucleic acid design limit the extent to which carriers 
and nucleic acids can be modified, and their properties tuned, towards higher transfection 
efficiency and effectiveness in nonviral gene delivery.  It may be necessary to employ 
additional methods to modulate the cellular response to transfection in order to achieve 
clinically relevant transfection efficiency and transgene expression in vivo.  One 
approach is to pharmacologically prime cells with chemical compounds before, during, or 
after delivering carrier nucleic acid complexes to cells in order to improve some aspect of 
the gene transfer process.  This approach has been demonstrated to have merit in some 
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studies which are discussed below.  It appears that priming enhancement of transfection 
efficiency and transgene expression can be through direct modulation of the barriers to 
gene delivery, or indirect through modulation of the cellular response to transfection in 
terms of toxicity and altered gene expression. 
 
1.5.1 Priming compounds that enhance internalization and endosomal escape 
 
Streptolysin O (SLO) is a bacterial endotoxin that forms pores in cell membranes, 
permeabilizing the membrane and allowing diffusion of molecules of up to 100kDa 
across and into cells [43].  With low doses of SLO treatment, toxicity to cells can be 
minimized, and the pores in the cell membrane can be resealed by treatment with a low 
concentration of Ca2+ ions.  After permeabilization and resealing with this low dose SLO 
and Ca2+ method, cells demonstrate internalization of external molecules as well as 
measures of recovery to normal phenotype and cellular processes [43].   This technique 
has been used in delivering both proteins [43] and nucleic acid [44] into cells in vitro. 
 Chloroquine is an antimalarial compound that has been demonstrated to enhance 
nonviral gene delivery in transfections across several nanoparticle carrier formulations 
[45].  A primary mechanism by which chloroquine priming enhances gene delivery is 
through buffering of endosomes, aiding complexes in escaping the endosome and 
avoiding lysosomal degradation.  The buffering capability of chloroquine is attributed to 
its behavior as a weak base [45], similar to the proton sponge effect seen in PEI amine 
groups. The observation that chloroquine priming does not improve PEI transfection has 
been part of the evidence that PEI itself buffers endosomes through the proton sponge 
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effect to escape the endosomal compartment.  Chloroquine priming does dramatically 
enhance PLL transfection [46], which does not have the innate ability to escape the 
endosome that PEI has.  It has been shown through structure-function correlation studies 
[45] that chloroquine may also enhance transfection efficiency through aiding in 
unpacking of the nucleic acids from the carrier nanoparticle complex and possibly 
electrostatically interacting with nucleic acids in a way that alters intracellular processing 
or degradation. 
 
1.5.2 Glucocorticoid priming enhances transfection 
 
Glucocorticoid priming has been demonstrated to enhance viral and nonviral gene 
delivery across multiple cell types [47-49].  Recent work has shown that human 
mesenchymal stem cells (hMSCs), a primary cell type that is typically difficult to 
transfect, showed increases in transfection efficiency and transgene expression of up to 
10-fold across multiple donors, with dexamethasone (a synthetic glucocorticoid) priming 
prior to transfection [49].  qRT-PCR of cytoplasmic and nuclear fractions isolated by 
gradient centrifugation  subcellular fractionation showed that glucocorticoid priming 
increased total cellular and nuclear uptake of delivered plasmid in transfected cells [49].   
The specific mechanisms of this enhancement remain unclear, but preliminary data 
suggest that activation of cytosolic glucocorticoid receptors by glucocorticoid priming 
may improve internalization, nuclear translocation, and nuclear import of complexes 
[49].  
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1.5.3 Genes implicated in successful gene delivery are priming targets for enhancing 
transfection   
 
In studies by Martin and Plautz et al [50-52], enhancement of transfection 
efficiency and transgene expression were demonstrated by pharmacological priming with 
activators and inhibitors of genes which had been identified as differentially expressed in 
successfully versus unsuccessfully transfected HEK293T cells.  At various time points, 
fluorescence activated cell sorting (FACS) was used to sort cells which had been treated 
with polymer or lipid pDNA complexes encoding for enhanced green fluorescent protein 
(EGFP).  Microarray analysis was performed on sorted and control cell populations to 
create gene expression profiles for successfully transfected, unsuccessfully transfected, 
and control cells which had not been treated with carrier pDNA complexes.  Network 
analysis was then performed on the gene expression profiles to determine differentially 
expressed genes between the populations at each time point.  Table 1.1 below shows an 
abbreviated list of genes identified by these studies as being differentially expressed in 
successfully versus unsuccessfully transfected HEK293T cells in PEI transfection. 
 
Table 1.1: Differential gene expression between HEK293T cell populations sorted by 
successful and unsuccessful EGFP expression (adapted from [50]) 
 
Gene Role 
Differential Expression 
(fold change) 
RAP1A Cell adhesion 12.58 
CHORDC1 Heat shock 10.38 
NEB Cytoskeletal dynamics 7.81 
WDR78 Lipid rafts 6.96 
PGAP1 Lipid rafts 6.33 
ATF3 
Cell stress pathways (NF-Κb, 
JNK/SAPK) 
5.34 
IREB2 Oxidative stress 5.3 
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Furthermore, pharmacological activation or inhibition of these differentially 
expressed genes was shown to enhance or decrease transgene expression, demonstrating 
that genomic targets can be modulated by priming to enhance nonviral gene delivery.  
The results of these FACS/microarray studies also suggest that in addition to overcoming 
the primary barriers to transfection, nonviral gene delivery strategies may need to 
modulate the overall cellular response to transfection, including toxicity that causes cell 
stress and genomic effects, to achieve higher transfection efficiency and more sustained 
transgene expression.   
 
1.6 High throughput screening of gene delivery  
 
The examples of pharmacological priming described above suggest that priming 
may be an effective means for improving transfection in vitro.  Broad applicability of 
transfection priming to different carriers, nucleic acids, and cell types has not been fully 
established, but a next step would be to search for other compounds which might have 
priming effects, a drug discovery endeavor.  While drug discovery has historically been a 
matter of educated trial and error, the modern medical research and pharmaceutical 
industry has established high throughput screening methods to implement these searches 
in higher volume to accelerate the process [53]. 
Broadly, high throughput screens are based on the idea that multiple treatment 
conditions can be tested in parallel against a single target to determine which of the 
treatments have desired effects on the target.  In high throughput screens for drug 
discovery, the treatments are large arrays of drug molecules in various stages of 
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development tested against cellular targets for which the drugs could be further 
developed.  These cellular targets can be bioactive molecules such as signal transduction 
receptors [54] and antibodies [55], or live cultured cells [56, 57].   
An example application of high throughput screening for identification of novel 
drugs is the identification of antiviral compounds.  A recent study performed a high 
throughput screen to identify broad spectrum antiviral molecules against zoonotic viruses 
(SARS coronavirus and Ebola, Nipah, and Hendra viruses) [58].  The approach was to 
search for compounds that inhibited CatL cleavage of viral glycoproteins, a process 
required by SARS, Ebola, Nipa, and Hendra viruses, without inhibiting the CatL enzyme 
itself (to preserve endogenous host functionality of the enzyme). Representative peptide 
sequences for each virus were synthesized and labeled with both a light quencher and 
light emitter for a FRET signal which reported cleavage of the peptide.  The initial screen 
of 5,000 small molecules revealed compounds that inhibited CatL cleavage of SARS 
peptide, the top 50 of which were rescreened for broad spectrum inhibition of CatL 
cleavage of Ebola, Nipa, and Hendra peptides, while minimizing inhibition of CatL 
cleavage of host peptides.  The screen was successful in identifying a molecule that was 
an effective broad spectrum antiviral against all four zoonotic viruses. 
High throughput screening methods have also been applied to genome-scale gene 
expression through siRNA library screens [59] and DNA microarray screens [60].  In 
DNA microarray screens, nucleic acid probe sequences representative of the entire 
human genome are tested for complementary hybridization against mRNA samples to 
determine any and all gene expression associated with the sample.  This approach was 
utilized as described in 1.5.3 to identify differentially expressed genes in the human 
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genome of successfully versus unsuccessfully transfected HEK293T cells, with the 
samples being the mRNA extracted from the FACS sorted cell populations [50-52].  
These samples were tested in high throughput for hybridization against tens of thousands 
of probes in parallel, with each probe corresponding to a unique gene in the human 
genome, producing a comprehensive dataset identifying differentially expressed genes in 
successful polymer and lipid mediated gene delivery, providing a holistic context for 
nonviral gene delivery strategies to be developed which account for the total cellular 
response to transfection. 
High throughput RNAi screens with genome-scale siRNA libraries are similar to 
DNA microarrays in that they examine gene expression at the genome wide level; 
however siRNA screens search for genes and proteins which are involved in a process by 
knocking down gene expression [59], in contrast to DNA microarrays which identify 
genes that are expressed through mRNA in a tested sample.  For example, a recent 
genome wide siRNA high throughput screen revealed genes which are involved in 
regulation of interleukin-8 secretion, revealing new information about the mechanisms 
which contribute to the inflammation of the intestine in Crohn’s disease [61].  The DNA 
microarray studies in 1.5.3 identified gene pathways involved in successful transfection 
followed by secondary modulation of these genes pharmacologically; a similar yet 
different differential gene expression screen can be performed from an RNAi silencing 
approach that combines identification of genes involved in gene delivery and modulating 
those identified genes directly through mRNA silencing by siRNA into one step, instead 
of a two-step process which involves indirect pharmacological modulation of the gene.  
This also implies that siRNA and not only pharmacological compounds are capable of 
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priming effects on gene delivery, and should be considered potential candidates as 
priming agents as well.   
There are other ways high throughput screens can be specifically applied to the 
application of gene delivery as a design tool.  For example, high throughput screens have 
been performed for optimization of transfection with lipid and polymer carrier complex 
formulations.  In these screens, different variations of a carriers design are tested in high 
throughput transfection of cell arrays to reveal candidates whose design optimally 
improves their efficacy in transfection.  For example, a high throughput screen tested 144 
variants of low MW linear and branched PEI (423-Da and 1.8kDa) biodegradably 
crosslinked together with oligo-acrylate esters, under the premise that a high effective 
MW PEI-based polymer can retain optimum transfection efficiency while also being 
degradable to lower MW constituents to minimize toxicity [62], as has been 
demonstrated previously [40].  The screen successfully identified vectors which exhibited 
potency twice as high as 22-kDa linear PEI, while being less toxic. 
The reporter proteins used to measure transgene expression in high throughput 
screens of gene delivery can generally be assayed by colorimetric or luminescent 
reactions, or fluorescence imaging.  Fluorescence is easily multiplexed, allowing for 
multiple fluorophores of different excitation and emission wavelengths to be imaged 
simultaneously.  Multiplexing multiple readouts in a screen is generally referred to as 
high content screening.  A recent study performed a high content screen of different PEI 
formulations and was able to localize rhodamine labeled PEI within cells by fluorescence 
microscope imaging, multiplexing rhodamine labeled PEI, GFP reporter protein, and 
Hoechst DNA stain, and demonstrating the utility of a high content screening approach in 
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the context of nonviral gene delivery [63]. Multiplexing of fluorophores allows for 
multiple readouts from a single screen, allowing for simultaneous measurement of not 
only transgene expression, but other measurements as well, such as cell viability and 
proliferation.  A similar multiplexed fluorescence readout high throughput and high 
content screening approach was utilized in the research of this thesis which is presented 
in Chapter 2. 
 Finally, to the extent of the literature search for this thesis, two high throughput 
screens have been applied to the search for compounds which enhance gene delivery, 
specifically priming adjuvants for delivery of oligonucleotides as well as viral 
transduction.  The most recent of these studies was the high throughput screen for 
compounds that enhanced antisense and splice switching oligonucleotide (ASO and SSO) 
delivery and activity [64].  ASO selectively degrade target mRNA in the cytoplasm, 
while SSO modulate splicing of pre-mRNA in the nucleus [65].  The primary hits were 3-
deazapteridine analogs which, in vitro, showed enhancement of activity of both ASO and 
SSO, with modest toxicity, in the low micromolar range. 
The second of these high throughput screens for priming agents, was a high 
throughput screen for priming of viral transduction, where siRNA and chemical 
compounds were screened for priming of transduction efficiency and transgene 
expression, identifying both siRNA sequences and chemical probes which prime viral 
transduction [66, 67]. Priming compounds which enhanced transduction included 
antioxidants, tyrosine kinase inhibitors, nucleoside analogs, alkylating agents, metal 
chelators, and cell cycle arrestors [66].  The most potent siRNA sequences identified in 
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enhancing transduction contained consensus sequences which were concluded to 
modulate the interferon pathway response to viral infection [67].   
The successful identification of priming compounds for viral transduction and 
oligonucleotide delivery by high throughput screens suggests that it should be possible to 
identify compounds that enhance pDNA delivery using nonviral methods by the high 
throughput screening methods performed in this thesis research, described in Chapter 2. 
 
1.7 Drug repurposing 
 
 In addition to using high throughput screening methods to search for priming 
compounds, a drug repurposing approach was also taken in this thesis research to 
increase the expected bioavailability and biocompatibility of potential priming candidates 
identified by the screen, with the objective being to find priming compounds that are 
already clinically accepted, like the glucocorticoids are [49].  For this purpose, the NIH 
Clinical Collection was used [68].  This collection of 725 compounds is provided by the 
NIH for drug repurposing research, and the goal of this thesis research was to identify 
potential clinically approved compounds from this collection for repurposing to priming 
of nonviral gene delivery. High throughput screens of the NCC have already been 
performed to repurpose compounds for antiviral [69, 70], anti-cancer [71], and other 
applications [72].  
High throughput methods accelerate the process of drug discovery, but 
pharmaceutical development costs remain high, an estimated $800,000,000 [73] to bring 
a drug to market.  In the specific application of drug discovery to transfection priming 
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compounds, this expense may be justified in the future, if priming adjuvants become 
widely adopted as an integral aspect of effective gene therapy, but presently, preliminary 
research into transfection priming should seek compounds that have a low development 
cost and are known to be biocompatible and bioavailable. 
 There are various metrics that are generally used to predict suitability of 
compounds as pharmaceutical compounds. ADME (absorption, distribution, metabolism, 
and excretion) is an acronym which describes some of the main processes a drug 
encounters within an organism [74]. Additional considerations are toxicity and liberation, 
which describes the release of drug from delivery vehicle. With respect to drug 
properties, Lipinsky’s rule of five suggests guidelines that increase the chances a 
compound will have desirable behavior in vivo [75]: 1) Molecular weight less than 500 
Daltons. 2) Less than five hydrogen donors. 3) Less than 10 hydrogen acceptors. 4) 
octanol-water partition coefficient (logP) less than five.  It is not trivial to design a drug 
that has a specific target effect while also optimizing these parameters and properties, one 
reason for the extensive cost and time of drug development. 
 
 
Figure 1.4 Drug-like properties of the NIH Clinical Collection [68] 
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From Figure 1.4 shown above, the drug-like properties of NCC compounds are 
already well defined and can be seen to adhere to Lapinsky’s rule of five, making the 
NCC an ideal starting point for a high throughput screen to discover priming compounds 
for nonviral gene delivery.   
 
1.8 Thesis objectives 
 
 In summary of this chapter, the rationale for a high-throughput and high-content 
screen of clinically approved compounds for priming of nonviral gene delivery has been 
presented.  Priming is an emerging tool for improving transfection outcomes, with 
potential to be incorporated into overall efficient nonviral gene delivery strategies 
through understanding and modulation of the barriers to transfection as well as the total 
cellular response to transfection, and a high throughput fluorescence imaging screen of 
the NCC is an ideal method of discovering additional priming agents.  Chapter 2 will 
describe and discuss in detail the design, implementation, and results of this screen, while 
Chapter 3 will elaborate on future work which the screen suggests.   
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CHAPTER 2 
High Throughput Screening of Priming Candidates for Impact on Nonviral Gene 
Delivery 
 
2.1 Introduction 
 
Gene delivery is the delivery of exogenous DNA into cells, and can be 
accomplished by viral and nonviral methods, however viral methods have safety concerns 
and design constraints [5], while nonviral methods lack efficiency [12].  Attempts to 
improve nonviral gene delivery strategies have, to date, generally hinged on the careful 
design of carriers and nucleic acid cargo [24, 76], however, their optimization may not 
alone be sufficient to achieve clinically relevant transfection efficiency, transgene 
expression, or gene silencing.  This lack of efficiency may be due to a host of cellular 
pathways associated with both successful and unsuccessful nonviral delivery [50, 51], 
and these pathways may have more to do with the overall cellular response to being 
transfected, than the ability of carrier complexes to overcome the barriers to transfection, 
or the ability of delivered nucleic acids to have their desired effects.  It could be possible 
to further optimize carriers and nucleic acids to induce an appropriate cell response and 
avoid an undesirable cell response, in addition to fulfilling their current design criteria; 
however, further modifications to intricate carriers adds complexity to a challenge that is 
already fairly intractable.  Modulating these cellular response pathways by other means, 
perhaps pharmacologically [50, 51, 77] or through substrate interactions [78, 79], may 
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decrease the design burden on the transfection complexes and allow effective nonviral 
gene delivery strategies to be developed. 
Pharmacological treatment of cells prior to transfection, i.e. priming, can enhance 
or knockdown transfection efficiency and gene expression. For instance, pharmacological 
modulation of genes found to be differentially expressed in, successfully versus 
unsuccessfully transfected HEK293T cells, resulted in up to five fold increases and five-
fold decreases in transfection [50, 51].   Another example of priming is work which 
demonstrated that glucocorticoid priming markedly improved gene delivery to hMSCs in 
vitro, a cell line which is difficult to transfect, enhancing transfection over 10-fold across 
five human donors [77].  These results suggest that priming is a tool that should be 
investigated for enhancement of nonviral gene delivery. 
 To efficiently search for compounds which may have priming effects on 
transfection, an obvious starting point is to screen clinically approved compounds.  
Previous clinical approval of a compound suggests acceptable biocompatibility and 
bioavailability of the compound in vivo, which would be primary criteria for 
incorporating priming into the design of gene delivery applications.  If clinically 
approved compounds can be repurposed for priming, the drug discovery and development 
costs of viable priming compounds could be dramatically decreased.   
For this purpose, the NIH provides the NIH Clinical Collection (NCC) [68], a set 
of 725 clinically approved compounds to be screened for repurposing.  Several studies 
have successfully performed high throughput screens of the NCC to repurpose the drugs 
for their potential antiviral [69, 70], regenerative [72], chemotherapeutic [71], and other 
[80-82] properties.  High throughput screening of gene delivery has been attempted, 
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mostly for optimization of polymer [62, 83], lipid [84], and peptide [85] carriers.  Perhaps 
most relevantly to this thesis, a high throughput screen has been conducted for priming of 
viral transduction with siRNA and  chemical compounds [66, 67], which identified 
several siRNA sequences and types of compounds (antioxidants, metal chelators, 
alkylating agents, nucleoside analogs, cell cycle arrestors) to have priming effects on 
viral transduction.  The research in this thesis attempts a similar screen, though of 
clinically approved compounds from the NCC, for priming of nonviral gene delivery, 
with the goals being to identify an assortment of priming adjuvants for transfection, and 
to improve our understanding of the biology of transfection through investigation of their 
priming mechanisms.  
The specific methods used in screening for enhancement of gene delivery can 
vary, but generally, cell arrays are transfected with bolus and/or substrate mediated 
delivery of DNA complexes [86].  Priming screens involve treatment of these cell arrays 
with compounds for a certain amount of time before transfection with complexes 
delivering plasmids encoding for common reporter genes like β-galactosidase (LacZ), 
luciferase (Luc), and green fluorescent protein (GFP), which are often used as markers 
for expression of co-transfected genes.  Quantification of LacZ and Luc expression are 
colorimetric and luminescence assays, respectively, while GFP can be quantified by 
fluorescence measurement.  A key benefit of using a fluorescent reporter for gene 
expression is the ability to easily multiplex fluorophores, like Hoechst and propidium 
iodide, for multiple readouts.  Because of this, high throughput screens that utilize 
fluorescent reporters are generally also high content imaging screens [63, 72, 85], which 
can reveal information on cell viability, cell proliferation, cell cycle, cell morphology and 
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more, depending on the fluorescent markers and image processing methods used, 
valuable information to consider for assessing the various responses a cell may have to 
priming and transfection in addition to overall transfection efficiency and transgene 
expression.  
We hypothesized that application of a high content fluorescence imaging 
methodology to high throughput screening of clinical compounds for priming of nonviral 
gene delivery would reveal drugs, or even classes of drugs, which modulate transfection 
efficiency and/or transgene expression.  We chose to use 25 kDa branched 
polyethylenimine (PEI) as our polymer carrier because it achieves moderate, reliable, and 
cheap transfection, with room to increase or decrease in efficiency and gene expression, 
depending on the priming effect observed.  Another reason was that 25 kDa branched PEI 
was also tested as a transfection carrier in the previously discussed transfection gene 
expression profiling experiments [50, 51], the data from which we intend to perform 
network analysis upon in combination with the data from this screen.  
In testing our hypothesis, we hope to validate the screen methods and demonstrate 
that transfection priming is a promising undeveloped tool for improving transfection, 
identifying clinical compounds and drug classes from the NCC whose priming effects 
have potential to be incorporated into efficient nonviral gene delivery strategies through 
understanding and modulation of the cellular response to transfection.   
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2.2 Materials 
 
2.2.1 HEK293T cells 
 
 
Figure 2.1. Phase contrast microscope image of cultured HEK293T cells. 
 
HEK293 are an existing mammalian cell line created from human embryonic 
kidney cells of an aborted embryo, which were immortalized by adenovirus type 5 
transformation [87]. The HEK293T variant of this cell line was further transformed to 
express the simian virus 40 (SV40) T antigen, which is a viral transcription factor for 
gene sequences that contain the SV40 promoter region, a reason HEK293T cells are 
commonly used for both transient and stable recombinant protein expression [88]. 
Plasmids encoding genes with CMV and SV40 promoters are highly expressed in these 
cells upon successful transfection, making them an ideal cell line for studies of nonviral 
gene delivery [89]. 
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In this screen, HEK293T cells were cultured in Falcon T25 flasks (Fisher 
Scientific) in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) 
completed with 10% fetal bovine serum (Life Technologies), 1% Penicillin/Streptomycin 
(Life Technologies), and 1% sodium pyruvate (Life Technologies).  Cells were incubated 
at 37 °C, 5% CO2, and passaged using 1 mM ethylenediaminetetraacetic acid in PBS 
(EDTA) (SigmaAldrich) at 75%-85% confluence approximately every 48 hours, with 
passage number ranging from 15 to 35 over the course of the screen.  
 
2.2.2 pEGFPLuc plasmid 
 
 
Figure 2.2. pEGFPLuc plasmid map [90]. 
 
The pEGFPLuc plasmid encodes for a fusion protein of enhanced green 
fluorescent protein (EGFP) and luciferase.  EGFP is a red-shifted variant of wild-type 
green fluorescent protein (excitation/emission maxima at 488nm/507nm), while is an 
enzyme that catalyzes a luminescent reaction of luciferin substrate [90]. Both are 
common reporters for transfection efficiency, with this fusion providing a co-transfection 
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marker that is measurable with both fluorescence and luminescence quantification 
methods.  The EGFPLuc sequence is flanked by a human cytomegalovirus (CMV) 
promoter and an SV40 polyadenylation tail, with the plasmid backbone also containing 
an SV40 origin [90], for expression in mammalian cells, especially those expressing 
SV40 T antigen, as the HEK293T cells used in this screen do [87].  
Neomycin and kanamycin resistance are also encoded in this plasmid, with a 
bacterial promoter, SV40 promoter, and HSV TK polyadenylation tail, allowing for 
propagation and selection in E. coli, by treatment with kanamycin, as well as selection of 
stably transfected mammalian cells, by treatment with G418 (Geneticin) [90]. For this 
screen, pEGFPLuc (Clontech) was propagated in E. coli, selected by kanamycin 
treatment, isolated from the E. coli using Qiagen Giga Prep (Qiagen), and prepared in 
endotoxin-free TE buffer at 1mg/mL, with purity assured by NanoDrop absorbance ratios 
at 260/280 and 260/230 of approximately 1.8 and 2.0-2.2, respectively [91], and 
subsequently stored in frozen aliquots at -20 °C.  A single 1 mL aliquot was sufficient for 
all transfections in this screen. 
 
2.2.3 Polyethylenimine (PEI) 
 
PEI is a cationic polymer carrier for nonviral gene delivery that serves as a gold-
standard to which newly developed carriers are often compared, as it reliably overcomes 
the primary barriers to transfection of cultured mammalian cells: internalization, 
endosomal escape, and nuclear transport [92]. In this screen, the commonly utilized 25 
kDa branched PEI (SigmaAldrich) variant was used, prepared at 1 mg/mL, dissolved at 
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80 °C, in 0.1 M sodium bicarbonate, in ddH20, at pH 8.2.  The 2 mL aliquots were frozen 
and stored at -80°C, with a new aliquot thawed for use weekly and kept at 4 °C. Aliquots 
were vortexed for 30 seconds before use in forming complexes with plasmid (as 
described in Methods 2.3.4) for delivery to HEK293T cells. 
 
2.2.4 NIH Clinical Collection 
 
Restated simply, the primary objective of this screen was to identify, with high 
throughput methods, existing clinical compounds that prime cultured cells for nonviral 
gene delivery.  The particular collection of pharmacological compounds screened was the 
NCC from the NIH Small Molecule Repository [68], which is provided to researchers 
endeavoring to repurpose clinically approved pharmaceutical compounds.  The 725 
compounds of the NCC were received in ten, 96-well plates, with 10 μL of each 
compound (10 mM) in dimethyl sulfoxide (DMSO).  Each plate was empty in the 16 
wells of columns 1 and 12 (See Figure 2.3 below), with eight of the plates populated with 
one compound per well in the 80 remaining wells, and the two other plates populated 
with approximately 40 compounds.  The 2 μL aliquots of each compound were prepared 
in four 96-well plates per original NCC plate, and kept frozen at -20 °C to be thawed 
before use. 
 
 
Figure 2.3. NIH NCC 96-well plate, compounds in columns 2 through 11. 
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2.2.5 Hoechst 33342 DNA stain 
 
Hoechst 33342 fluorescent dye was used to stain cell nuclei and enable cell count 
of fluorescence microscope images at low magnification and resolution.  Hoechst stained 
nuclei require minimal image processing to automate a cell count for each image. 
Hoechst 33342 is a DNA intercalating dye with excitation/emission maxima at 
355nm/465nm when bound to DNA, which is permeable to the cell membranes of live 
cells, and is sufficiently non-toxic to allow for endpoint live cell imaging [93]. 
In addition to cell count and proliferation, Hoechst 33342 also provides 
information on cell cycle and cell death processes, as Hoechst staining kinetics depend on 
chromatin packing, amount of DNA in the cell (dependent on cell cycle), and 
permeability of the cell and nuclear membranes [94].  The integrity of cell and nuclear 
membranes is impaired in apoptotic and necrotic cells.  Hoechst 33342 stock solution was 
prepared from lyophilized powder (Sigma Aldrich), dissolved in ddH20 at a 
concentration of 10 mg/mL, and stored at 4 °C.  
 
 
Figure 2.4. Hoechst structure [95]. 
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2.2.6 Resazurin metabolic indicator 
 
Resazurin is a reagent that is commonly used to measure proliferation and 
viability of cultured cells. Resazurin solutions are a nonfluorescent blue, but become 
reduced to pink resofurin in the presence of metabolic activity of cells, which fluoresces 
with excitation/emission maxima at 530nm/590nm  [96]. Unlike MTT assays, resazurin 
does not require cell lysis, allowing for repeated viability measurements over time in 
some applications, such as lymphocyte proliferation [97], though long term incubation 
with resazurin has been shown to have some cytotoxic effects, recommending its use as 
an endpoint assay [96].  Compared to WST-1 colorimetric assays (which also do not 
require cell lysis) resazurin is much lower in cost, and its measurement by fluorescence 
allows for multiplexing in live cell imaging applications by fluorescence plate reader 
measurement.  Stock resazurin solution was prepared from lyophilized resazurin sodium 
salt powder (SigmaAldrich), dissolved in PBS at a concentration of 10 mg/mL, and 
stored at 4 °C. 
 
 
Figure 2.5. Resazurin (left) and Resofurin (right) [98]. 
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2.2.7 Rationale for fluorophore selection 
 
For multiplexing applications, the excitation and emission spectra of the 
fluorophores must be sufficiently separated to not have cross talk between the signals.  
Figure 2.6 below shows the excitation and emission spectra for Hoechst 33342, EGFP, 
and Resazurin, the fluorophores used in this screen.   
 
 
Figure 2.6. Fluorescence spectra of Hoechst 33342, EGFP, and Resazurin [99] 
 
 
There were several fluorescent markers that could have been used for each 
measurement (in this screen, gene expression, cell enumeration, and viability), each with 
different excitation and emission wavelengths.  Other considerations included quantum 
yield, sensitivity to photobleaching, permeability to the cell membrane, toxicity, etc.  
EGFP was chosen for its convenient availability in our lab as a fusion protein with 
luciferase, which adds a potential chemiluminescent measure of gene expression to the 
screen.  EGFP left the blue and red emission wavelengths open for cell counting and 
viability dyes.  Dyes that enable cell counting come in many forms, from nuclei stains to 
cytoskeletal and membrane stains.  Cytoskeletal and membrane stains generally require 
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the fusion of fluorophores to antibodies of the proteins found in those features, while 
nuclei stains naturally and specifically target and bind DNA.  For this reason, the blue 
nuclei stain Hoechst 33342 was chosen, as well as for its permeability to live cell 
membranes.  For viability measurements from the remaining red emission wavelengths, 
there were several options.  Higher permeability of certain DNA dyes into unhealthy cells 
with compromised membranes compared to healthy cells with intact cell membranes is 
one method of differentially staining cells for viability, with such dyes including 
ethidium bromide and propidium iodide.  Another type of viability measuring dyes is 
metabolic indicators, which interact with the reducing environment of the cell to become 
fluorescent, an example of which would be resazurin.  One benefit of resazurin in 
comparison to ethidium bromide and propidium iodide is that it is very inexpensive in its 
unbranded form.  One thing to note is that resazurin cannot be imaged only inside cells, 
because its reduced form resofurin is also permeable to the cell membrane and does not 
remain localized within cells, diffusing back out into surrounding media.  This does not 
preclude it from use as a measurement of cell viability though, and in the end, resazurin’s 
metabolic measurement, similar to WST-1 and MTT assays, was deemed more sensitive 
to potential priming toxicity than permeability of dyes to the cell membrane. 
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2.3 Methods 
 
2.3.1 Screening schedule 
  
 
Figure 2.7.  Screen timeline 
 
The screen of the 725 clinically approved compounds in the ten 96-well plates of 
the NIH NCC, for priming of PEI/pEGFPLuc transfection of HEK293T cells, was 
accomplished over the course of one month.  In brief, cells were seeded in 96-well plates, 
primed 17 hours after seeding, transfected one hour after priming, and imaged (as 
described below) 48 hours after transfection. For each NCC plate, four 96-well plates 
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total, the cell handling portion of the screen took approximately 120 hours to complete 
over the one month period. 
 
2.3.2 Seeding HEK293T cells for the screen 
 
Each T25 flask at typical confluence (75-85%) provided enough cells to seed two 
full 96 -well plates at a seeding density of 8,000 cells per well and seeding volume of 80 
μL per well. With each well having a surface area of 0.32 cm2, the seeding density was 
25,000 cells/cm2. This approximate seeding density was previously optimized in a 
preliminary screen that assessed PEI transfection efficiency in HEK293T cells by LacZ 
expression 48 hours after transfection   
To passage, cells were rinsed with phosphate buffered saline (PBS) (Life 
Technologies), detached from the flask surface by incubation in 400 μL of 1 mM EDTA 
in PBS for five minutes at 37 °C, then diluted to a total cell suspension volume of 4.3 mL 
in HEK293T media, with 1mL of this volume used for passaging to a new flask, and the 
remaining approximately 3.3 mL available to seed plates for the screen.  
Each well was seeded with 80 μL of diluted cell suspension, requiring a minimum 
of approximately 15 mL dilute cell suspension for two full 96-well plates, however, an 
excess dilute cell suspension of 25 mL was used, in an attempt minimize variation in 
seeding density due to volume change as the suspension is used.  At typical cell counts, 
between approximately 1.5-2 mL of the cell suspension was diluted to 25 mL for the 
desired 105 cells per mL concentration.  This 25 mL suspension was split into four 
volumes of approximately 6.25 mL, with two of these volumes being used to seed each 
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plate.  Before seeding, each volume was inverted to mix, then transferred to an 
autoclaved fluid reservoir for an eight channel pipette, where they were then triturated to 
mix further.  From these well mixed suspensions, an eight channel pipette was used to 
seed.  Six rows were seeded with every 6.25 mL volume, at 80 μL of cell suspension per 
well, to seed all wells of two 96-well plates.  These plates were briefly examined under 
phase contrast to ensure the seeding density was uniform, and then transferred to an 
incubator (37 °C, 5% CO2) for the cells to adhere over 17 hours before priming and 
transfection. 
 
2.3.3 Priming HEK293T cells with NCC compounds 17 hours after seeding 
 
 From each stock NCC plate, four aliquot plates were made, containing 2 μL of 
each compound per well at 10mM in DMSO.  This screen required one aliquot plate from 
each stock NCC plate to complete the screen of every compound in the collection at both 
5 μM and 50 μM. These concentrations are relative to the 141 μL total liquid volume 
added to the wells in seeding, priming, and transfecting. The following descriptions are of 
the priming compound preparations of one aliquot plate of the NCC collection, which 
were repeated for all ten of the NCC plates.  To prepare the compounds from an aliquot 
plate for delivery to cells, the plate was thawed for 15-30 minutes at room temperature 
prior to dilution in HEK293T media, while the HEK293T media was concurrently 
warmed to 37 °C in a water bath.  As vehicle controls, 2 μL DMSO was added to each of 
the empty wells of columns 1 and 12 of the aliquot plate (Figure 2.4 for reference).  To 
dilute the aliquot plate for the 50 μM priming concentrations, and equivalent 1.4% 
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DMSO (v/v) in the vehicle control wells, 111.48 μL of warmed HEK293T media was 
added to each well of the aliquot plate, triturating to mix well.  Approximately 17 hours 
after seeding two plates with HEK293T cells, 40uL of each compound of the aliquot 
plate were gently delivered by eight channel pipette into corresponding wells of both 
seeded plates.  The priming volumes were pipetted with the tips angled to gently dispense 
against the side of the wells and minimally disturb the cells in the wells.  The primed 
plates were then incubated for one hour at 37 °C, 5% CO2 before transfection.  Priming 
two plates requires 80 μL of each 50 μM compound, so there was approximately 31.5 μL 
remaining of the original 113.48 μL of each compound in the aliquot plate after priming 
both seeded plates.  The remainder of the 50 μM concentrations in the aliquot plate was 
frozen, to be thawed and diluted for priming at 5 μM within 24 to 48 hours.  To prepare 
the 5 μM priming concentrations, 12 μL of the thawed remainder of the 50 μM 
concentrations were diluted with 108 μl of warmed HEK293T media, triturating to mix 
well, before delivering 40uL of each compound to corresponding wells in two seeded 
plates.  The primed plates were then incubated for one hour at 37 °C, 5% CO2 before 
transfection. 
 
2.3.4 Transfection of HEK293T cells one hour after priming with NCC compounds 
 
DNA/PEI complexes were formed in Tris-buffered saline (TBS).  Previously, a 
preliminary screening experiment determined that 0.17 μg of pEGFPLuc, complexed 
with 0.34 μg of 25 kDa branched PEI at N/P ratio of 15, and delivered in a 21 μL TBS 
volume to each well, was an optimum formulation for this screen format.  For 
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transfection of two full 96-well plates, this formulation amounted to four pairs of 1.5mL 
microcentrifuge tubes consisting of 20.4 μL of 1 mg/mL 25 kDa branched PEI, in 471.91 
μL of TBS, to be mixed into 10.2 μL of 1 mg/mL pEGFPLuc, in 728.26 μL of TBS.  The 
total volume ratio of DNA to PEI tubes was 60:40. To form the complexes, the PEI tubes 
were pipetted into the pEGFPLuc tubes, triturated five times, vortexed for 10 seconds, 
and then incubated at room temperature for 15 minutes.  After the incubation, the 
complexes were combined into an autoclaved fluid reservoir to be dispensed at 21 μL per 
well into all wells of both plates, by eight channel pipette, after one hour of incubation 
with priming compounds. 
 
2.3.5 Staining HEK293T cells 48 hours after PEI transfection 
 
After a 48 hour incubation following transfection, at 37 °C, 5% CO2, the primed 
and transfected HEK293T plates were stained with Hoechst and Resazurin fluorescent 
dyes to enable subsequent nuclei counts and viability assessments, respectively, 
multiplexed with the EGFP fluorescent reporter for transgene expression.  The staining 
solution consisted of 38.5 μL of 10 mg/mL Hoechst 33342 stock solution, and 22 μL of 
10 mg/mL Resazurin stock solution, in 22 mL of warmed Fluorobrite DMEM 
(ThermoFisher).  Instead of aspirating the wells before rinsing and staining, the plates 
were “flicked” upside down several times over a container which caught the ejected 
liquid.  Flicking two plates was much faster than aspirating each well, did not noticeably 
detach cells from the plate bottoms, and left small volumes of liquid in each well, 
preventing bare air exposure of the cells. Plates were flicked and rinsed with 100 μL of 
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PBS per well, and flicked again before 100 μL of the staining solution was added to each 
well.  The plates were then incubated for 30 minutes at 37 °C, 5% CO2.  Care to avoid 
exposure of the dyes to light was taken throughout the staining process, to prevent 
photobleaching. 
 
2.3.6 Fluorescence microscope imaging of screen plates 
 
After incubation with the staining solution, plates were imaged using a 
DMI3000B manual inverted microscope (Leica) with DFC340FX digital camera (Leica), 
EL-6000 mercury halide lamp (Leica) for fluorescence excitation, and LAS software 
V4.0 (Leica) for digital image viewing and capture.  Filters for excitation and detection at 
the EGFP and Hoechst wavelengths (488nm/509nm and 355nm/465nm, respectively) 
were used to take grey scale images of their fluorescence, in addition to phase contrast 
images.  Images were taken with a 5x objective (HCX FL PLAN 5X/0.12), center well.  
Cells were manually focused in phase contrast, with the focus unchanged for the EGFP 
image, and unchanged or with minor focus adjust for the Hoechst image to bring into 
focus as many nuclei as possible.  Phase contrast images were captured at 473 μs 
exposure (gain 1x, gamma 1.00), while EGFP and Hoechst fluorescence images were 
captured at 108.6 ms exposure (gain 2.0x, gamma 1.15).  Consistent fluorescence 
excitation lamp intensity (second highest setting) was used for all EGFP and Hoechst 
images in the screen.  Keeping those settings consistent allowed for comparison of image 
intensities between wells in the same plate.  Using these settings was also much faster 
than auto-exposure by the software, allowing for faster overall imaging times, which 
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averaged to about 45 minutes per plate (acquiring phase contrast, EGFP, and Hoechst 
images for every well) and 288 images per plate.  Wells were imaged down each column 
from row A to row H, from column 1 through column 12.  Images were captured at 
1600x1200 pixels in 8-bit TIFF image format.  Figure 2.8 below shows plate montages of 
EGFP and Hoechst fluorescence images acquired from a typical plate in the screen.  
 
 
Figure 2.8. EGFP and Hoechst images acquired from a typical plate in the screen, 
stitched together to form montages which resemble the 96 well plate format. 
 
 
Figure 2.9(a) is a phase contrast microscope image of a typical vehicle control 
well in this screen, taken with a 5x objective, center well.  Figure 2.9(b,c) shows the 
fluorescence microscope images of Hoechst and EGFP taken of the same well. These 
fluorescence images were pseudo-colored and overlaid by merging the images into RGB 
color format to provide a combined visual representation of transfection efficiency, 
transgene expression, and cell count, in one image, as shown in Figure 2.9(d). 
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Figure 2.9. Microscope images of a vehicle control well, in phase contrast (a) as well as 
EGFP (c) and Hoechst (d) fluorescence.  The fluorescence images were also pseudo-
colored and overlaid (d) 
 
 
 
 Initially, a primary concern was whether the cells would remain viable enough for 
the length of time required to manually acquire all images of a plate outside controlled 
temperature and carbon dioxide regulation.  The most obvious hindrance encountered in 
imaging for this length of time without environmental control was the water condensation 
on the lids of the plates, which caused uneven illumination and shadows between wells, 
shown in Figure 2.10 below. 
 
47 
 
 
Figure 2.10. Phase contrast image montage that demonstrates shadowing due to 
condensation on the plate lid. 
 
Phase images are difficult to process with uneven illumination and shadows due 
to their bright-field background illumination.  To normalize these variations between all 
wells would require the development of image processing algorithms beyond the current 
scope of this screen, so phase images were acquired in the screening process but not 
processed.  There is potential for future processing of these images to reveal information 
about overall cell morphological changes due to priming and transfection.   
Fluorescence images did not have the same uneven background signal, and were 
more easily processed for intensity and count measurements.  The important acquisition 
parameters were excitation intensity, detector exposure time, image location within the 
well, and focus.  The lamp and detector parameters were kept consistent for the entire 
screen, while image location within wells was kept as consistently center of the well as 
possible by, in phase contrast, aligning and centering the image area on the brightest area 
of the well, which is almost always the center of the well. The cells were also brought 
into focus while viewing in phase contrast. 
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The nearly hour long exposure of the plate to room temperature and unregulated 
CO2 did not noticeably affect the ability to capture representative images and quantify 
GFP or Hoechst fluorescence.  Cells were not seen to detach from the well surface.  The 
Fluorobrite DMEM imaging media was used due to its compatibility with live cell 
imaging, lacking phenol red that could interfere with the fluorescence measurements, and 
including glucose and sodium bicarbonate.  The manufacturer’s website also claims a 
higher signal to noise compared to PBS or other media formulations.  The Fluorobrite 
DMEM was used as is, without supplementing with FBS or L-glutamine.  It is important 
to note that imaging without temperature and carbon dioxide regulation was accepted for 
this endpoint imaging of cumulative transfection efficiency, gene expression, and cell 
number and viability after 48 hours of incubation post-transfection, not for more transient 
and delicate processes or with the intention to return these cells to the incubator for 
further culture, in which cases, environmental control would be required.  
 
2.3.7 Fluorescence plate reader measurement 
 
 In addition to microscope imaging, EGFP, Hoecshst, and Resazurin fluorescence 
was measured by a Synergy H1 plate reader (BioTek), with excitation/emission settings 
of 475nm/509nm, 355nm/464nm, and 545nm/590nm, and gain settings of 100, 50, and 
50, respectively.  Probe height was re-calibrated for each of these measurements for each 
plate by determining the probe heights that yielded maximum signal in a selected control 
well, and using those setting for the entire plate.  Gain and probe height were selected 
such that the signal was strong enough to be detected but also not saturating the detector.  
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The excitation wavelength used for EGFP was shifted away from the 488nm maximum 
down to 475nm, as the plate reader required the excitation wavelength to be sufficiently 
far from the emission wavelength.  At the EGFP, Hoechst, and Resazurin wavelengths, 
nine measurements were taken per well in a three by three array equally spaced within 
the well, from which mean intensities was calculated. The plate reader was used to 
quantify the amount of EGFP (transgene expression reporter), Hoechst (nuclei stain), and 
Resazurin (viability measure) in every well, to measure the effects each drug had on 
transfection and cell viability.  Hoechst was used as nuclei marker for cell counting by 
microscope image processing, but plate reader measurements were also acquired, as 
normalized Hoechst intensity may indicate cell cycle and cell death processes.  Figure 
2.10 below shows an example of these data for a typical plate of the screen, with heat 
map color shading to ease visual interpretation of the data.   
 
 
Figure 2.11. Typical plate reader measurements of EGFP, Hoechst, and Resazurin 
fluorescence. Darker shades indicate more intense fluorescence signal. 
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2.3.8 Comparison of microscope image and plate reader measurements 
 
For a comparison of plate reader and microscope images, see Figure 2.11 below.  
The well outlined in yellow immediately stands out as having an approximately two fold 
higher of EGFP than any other well in both the plate reader measurement and EGFP 
images.  Very low values in these measurements generally corresponded to wells having 
few cells due to toxicity of the priming condition, though in some cases, like the well 
outlined in red, there was very low EGFP expression with normal or high Hoechst and 
Resazurin readings, indicating normal or enhanced proliferation/viability.  
 
 
Figure 2.12. Comparison of plate reader and fluorescence microscope images 
showing qualitative similarity in the observed fluorescence by both methods. 
 
 
The primary limitation to the quantification of fluorescence through microscope 
images was the limited viewing area.  The culture area of a 96-well plate is pproximately 
32 cm2, while at lowest magnification (5x) the image area is approximately 5.9 mm2, so 
images capture approximately 18% of the well area.  Cells were always more densely 
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packed in the central area of the well, so there was always more than 18% of the cells in 
the well in the images, up to 100%, seeming to depend on the toxicity of the priming 
compound.  That being said, a significant portion of each well’s cell population was 
generally outside the image area.  The options for measuring the fluorescence from these 
cells were either taking images at multiple locations per well, or measuring with a 
fluorescence plate reader in an array scan.  The microscope imaging time of a full plate 
with three images per well (phase contrast, EGFP, and Hoechst, center well) was already 
45 minutes, so it was hard to justify adding more locations and time per well without 
environmental and CO2 control, unless there was no other option.  A 3x3 array scan 
covers approximately 24 mm2 of the well, 75% of the well area, and about four times the 
area of the microscope image.   
 
 
Figure 2.13. Microscope imaging and plate reader measurement areas, demonstrating the 
larger area coverage of the plate reader measurement but lower resolution. 
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The plate reader was able to measure fluorescence of EGFP, Hoechst, and 
Resazurin wavelengths, in 3x3 array scans per well, in approximately 15 minutes total 
per plate, about three times faster than microscope imaging of phase contrast, EGFP, and 
Hoechst.  The primary disadvantage of a plate reader measurement is that it only reads an 
array of intensities, rather than capturing a high resolution image that can be processed to 
extract more information, such as total cell counts and transfected cell counts, which 
were essential for normalization in this screen.  For these reasons, fluorescence 
microscope images and fluorescence plate reader measurements were both acquired for 
each plate.  Both of these measures were used in the hit selection and scoring process, 
considered individually and as part of overal transfection, proliferation, and viability 
scores. 
 
2.3.9 Cell lysis 
 
After imaging and plate reader measurements, cells were lysed for storage and 
potential future measurements of the lysate luciferase content.  For lysis of two full 96- 
well plates, 22 mL of 1x Reporter Lysis buffer (RLB) was sufficient, and was prepared 
by dilution of 4.4 mL of 5x Reporter Lysis Buffer (Promega) in 17.6 mL of ddH20.  Each 
plate was flicked and rinsed with 100 μL PBS per well, with 100 μL of 1x RLB then 
delivered to each well, after which the plates were incubated at room temperature for 5-
10 minutes before freezing and storage at -80 °C. 
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2.3.10 Image processing 
 
Macros in ImageJ (NIH), a Java based image processing program, were used to 
automate the mean fluorescence intensity measurements and maxima counts for the 
processing of the 11,520 images acquired over the course of the screen.  For each well, 
EGFP and Hoechst images were processed for average grey value, as the mean intensity 
EGFP and Hoechst fluorescence measurements, while local maxima were also identified 
to obtain counts of Hoechst stained nuclei and of EGFP expressing cells.  See Figure 2.14 
below for a representation of the image processing for each Hoechst and EGFP image for 
intensity and count, and Appendix B for the ImageJ macros used for the image 
processing in this screen. 
 
 
Figure 2.14. Hoechst nuclei and transfected cell counting by local maxima 
detection. 
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Average grey values of the Hoechst and EGFP images were determined using the 
“Measure” plugin in ImageJ.  Figure 2.14 shows total cells and transfected cells counted 
by the “Find Maxima” plugin in ImageJ.  The local maxima in the Hoechst and EGFP 
images were determined, point selected, and counted.  The noise tolerance of the “Find 
Maxima” plugin was adjusted to optimize detection and minimize misidentification of 
nuclei and EGFP cells.  These measurements were automated by macros in ImageJ.  
All microscope images were stitched together into image arrays to ease visual 
inspection of the 96 -well format, such as in Figure 2.15 below.  Similar image montages 
were created for every plate in the screen, for phase contrast, EGFP, Hoechst, and 
pseudo-color overlay images.  The processed image data were also compiled into 8x12 
spreadsheet arrays, the same format as the plate reader measurements.  The image array 
and image data in Figure 2.15 below, are from the same plate as the plate reader data 
shown in Figure 2.12, and show similar results. 
 
Figure 2.15. Image array aside image data processed from the images. 
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 The yellow box outlines a well which, by visual inspection, obviously had a 
relatively high amount of EGFP, reflected in the relatively high EGFP image mean 
intensity measurement, but did not have a relatively high image EGFP count, implying 
that the higher amount of EGFP in that well was due to an increase in EGFP expression 
in transfected cells rather than a higher number of transfected cells, a useful distinction to 
make when interpreting the data to explain the effects the various compounds might be 
having on gene delivery.  Similarly, the well outlined in red appears to have exhibited a 
large knockdown of both EGFP amount and transfected cell count, while exhibiting a 
high total cell count. 
 
2.3.11 Control filtering 
 
 Data were transferred to Excel (Microsoft) and Prism (Graphpad) for data 
processing and statistical analysis.  As seen in figure 2.16 below, there was variation in 
the Hoechst count of the transfected vehicle control wells in columns 1 and 12, which is 
due to variance in the initial seeding density.  Low initial seeding density in a well 
increases the number of transfection complexes available per cell, increasing transfection 
efficiency as well as toxicity in that well relative to other transfected vehicle controls 
wells.  To prevent potential unfair comparisons from control well transfection and 
toxicity bias due to initial seeding density which might result in discarding true priming 
candidates screened, as seen in Figure 2.16 below, transfected vehicle control wells 
which had total cell counts less than 95% of the mean of the vehicles controls as a whole 
for that plate were discarded from consideration for calculations of fold changes.  
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Figure 2.16 Demonstration of control filtering in the hit selection process 
 
2.3.12 Normalized fold change measurements 
 
 After filtering the controls, the image data for each well were normalized by their 
associated Hoechst total cell count or transfected cell count and their fold changes 
determined relative to the filtered vehicle control wells in columns one and twelve, as 
seen in Figure 2.17 below.  For example, the yellow outlined well was calculated to have 
a fold change increase in EGFP intensity per cell of 2.2, with no increase in transfection 
efficiency (% EGFP+) and a 0.7 fold decrease in cell count, while the red outlined well 
displayed a fold change decrease in both EGFP intensity per cell (0.18 fold) and 
percentage of cells expressing EGFP (.0003 fold), while exhibiting a fold increase in cell 
count (1.12 fold).  
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Figure 2.17. Normalized fold changes of EGFP measures and cell count.  
 
2.3.13 T-test and toxicity filter of normalized fold change measurements 
 
Data acquired for each well included: image measurements of EGFP intensity and 
count, and Hoechst intensity and count, as well as plate reader measurements of EGFP, 
Hoechst, and Resazurin intensities.  Each compound was tested in duplicate at both 5 and 
50 μM concentrations.  The fold changes of each measurement for each well relative to 
the filtered average vehicle control fold changes were then calculated, after which, the 
duplicate fold changes for each well were then grouped for unpaired two-tailed t-tests, 
assuming unequal variances, against the grouped filtered vehicle controls, to obtain a p-
value for the measurements of each compound 
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Figure 2.18.  p-value (top right) and Hoechst count fold-change (bottom right) versus 
EGFP image intensity fold-change.  It can be seen from this figure that compounds which 
appear to have high fold changes are often artifacts of wells which had extremely low cell 
counts. 
 
 
 
 These t-tests were not performed to assess significance, instead, the t-tests were 
used as an initial filter in the hit selection process, to throw out compounds whose effect 
size caused their –log(p-values) to be lower than the plate wide –log(average of p-values) 
for sample wells.  Figure 2.18 (top right) shows this filtering, with the compounds with –
log(p-values) less than –log(pavg) discarded from further consideration.  From the red and 
yellow arrows pointing at their corresponding compounds outlined in red and yellow on 
the image montage, it is obvious that a slight decrease in p-value threshold might have 
caused these wells to be mis-identified as false negatives, even though they clearly 
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deserve further investigation simply from visual inspection.  This t-test filtering was 
performed for all EGFP, Hoechst, and Resazurin measurements. 
  After the t-test filters, the cytotoxicity filters were implemented.  The first 
simply eliminates compounds which had normalized Hoechst count fold change 
decreases of less than 0.2, which were automatically discarded as extremely toxic, 
corresponding in Figure 2.18(bottom right) to the red region,  and the almost completely 
empty wells seen in the images of Figure 2.18(left).  From the remaining compounds, the 
average Hoechst count fold change was determined, including the blue and white regions 
of Figure 2.18(bottom  right), from which a minimum proliferation filter was 
implemented, one standard deviation below the average Hoechst count fold change of the 
remaining tested compounds in the plate, shown as the blue shaded region.  From the 
yellow and red arrows, it can be seen that both yellow and red outlined wells survive the 
toxicity filters for further consideration. 
 
2.3.14 Scoring and hit selection 
 
The next step in the hit selection process was to create a combined average fold 
change score for transfection, proliferation, and viability measurements of each 
compound tested.  The transfection (EGFP) score was determined by averaging the fold 
change in transfection efficiency with the four normalized fold changes of EGFP 
intensity.  The proliferation score was determined similarly, by averaging the four 
normalized fold changes of Hoechst intensity.  Lastly, the viability score was determined 
by averaging the two normalized fold changes in Resazurin intensity.  
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The highest and lowest transfection scoring compounds, up to ten each from each 
plate, were selected as potential hits, from which the preliminary hits for the screen were 
chosen, by inspection, based on transfection efficiency fold changes, transgene 
expression fold changes, and Hoechst count fold change in the screen data and images.  
Using Prism (GraphPad), one way ANOVA comparisons (Tukey’s post-test) were 
performed between EGFP transgene expression fold changes of the hit compounds and 
the plate vehicle controls.  From these ANOVAs statistical significance of the priming 
fold change effect over the vehicle was determined.  An example of these statistical 
analysis is demonstrated below in Figure 2.19, which shows how the fold changes for the 
duplicates of both concentrations relate to the transfected vehicle control wells.  The well 
outline in yellow is Ketorolac, a nonsteroidal anti-inflammatory drug that showed 
significant fold change increases at both 5 and 50 μM concentrations, while the well 
outlined in red is Epigallocatechin gallate that showed significant fold change decrease in 
transfection at both 5 and 50 μM concentrations as well.  
  
Figure 2.19. One-way ANOVAs for statistical analysis of duplicate normalized 
fold changes at 5 and 50μM 
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2.3.15 Preliminary screen verification 
 
 For a preliminary verification of the significant increases and decreases in 
transgene expression due to priming by the hit compounds identified by the screen, and to 
explore whether additional information could be revealed by luciferase and bicinchoninic 
acid (LUC/BCA) assay analysis of the screen lysate, compounds that were identified by 
the screen to significantly affect transfection (three compounds that increase transfection, 
and three compounds that decrease transfection) were tested in triplicate, in 48 well plate 
format, and assessed by LUC/BCA assay. The same seeding density, priming 
concentrations, and transfection conditions were used as in the screen, with volumes and 
amounts scaled from the 96-well to 48-well format by the same factor as the change in 
well growth surface area (0.32cm2 to 0.75cm2) 
 To quantify luciferase expression in cell lysate, 20 μL lysate samples were 
pipetted into 100 μL aliquots of LAR reagent (Promega), vortexed for 10 seconds, and 
measured by luminometer (Turner Designs).  To quantify total protein concentration in 
cell lysate by BCA assay, 50 μL of lysate samples were pipetted into 100 μL BCA 
working reagent (50:1 BCA Reagent A:B) (Pierce), incubated for 30 minutes at 60 °C, 
then measured for absorbance at 562nm by spectrophotometer. (Beckman Coulter) For 
statistics, one way ANOVA’s with Tukey’s post-test were performed in Prism between 
the tested conditions and the transfected vehicle control. 
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2.4 Results and Discussion 
 
Preliminary hit selection has been performed for four of the ten plates in the NCC 
thus far, producing 38 hits from 285 NCC compounds.  Listed in tables in Appendix A 
are the top performers in terms of transfection score from the four NCC plates, 
demonstrating priming increases and decreases at 5 both 50 μM (Tables A.1 through 
A.4).  To be clear, the entire NCC has been screened, data acquired and processed, 
simply the hit selection has not been performed on data from six of the plates. The EGFP 
Max/Min FC columns in Tables A.1 through A.4 denote the maximum or minimum 
average EGFP fold change in transfection measurements with priming by the NCC 
compound  (in terms of plate reader and microscope image measurements, normalized by 
either total cell count, or transfected cell count).  
From these lists, compounds were grouped to identify drug classes that prime 
transfection, identifying the 38 hits.  The identified drug classes are represented in Table 
2.1 below. This grouping was done by inspection, considering transgene expression and 
transfection efficiency fold changes, Hoechst count fold changes, and literature 
annotations of drugs class and known target receptors and pathways.  
 
Table 2.1 Preliminary hit compound grouping by drug class. 
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Statistical analysis of the hits in these drug classes was conducted by one way 
ANOVAs versus transfected vehicle controls, with Tukey’s post-test.  The observed 
priming effects of the drug classes outlined in red in Table 2.1 above are discussed 
below. 
 
2.4.1 Antibiotics decrease PEI transfection of HEK293T cells 
 
 
Figure 2.20 Antibiotic priming fold changes in transgene expression 
 
 Antibiotics appeared to generally knockdown transfection at the higher 50μM 
concentration, holding true for different classes of antibiotic, bactericidal and 
bacteriostatic, from cephalosporins, tetracyclines, to quinolones and fluoroquinolones.  
The generality of the effect over several different antibiotic classes and higher 
concentration at which the effect generally occurred seems to implicate a whole cell 
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response to priming by antibiotics that knocks down transfection, rather than an 
interaction with a very specific mechanism or pathway.   
From the literature, it seems that the primary off target effects of antibiotics in 
mammalian host cells are associated with mitochondria [100].  In the clinic, chronic 
antibiotic treatments have been observed to cause ototoxicity, nephrotoxicity, 
tendinopathy, and various other side effects [101].  The endosymbiotic theory which 
describes the origin of mitochondria suggest that they were prokaryotes that became 
incorporated into eukaryotes, so it is hypothesized that antibiotics target mitochondria 
due to their similarities to bacteria, causing mitochondrial dysfunction and production of 
reactive oxygen species. Induction of an oxidative stress response could explain the 
knockdown effect on priming which antibiotics seem to have on transfection. 
 
2.4.2 Stilbenoid and flavonoid antioxidants increase PEI transfection of HEK293T cells 
 
  
Figure 2.21 Stilbenoid priming fold changes in transgene expression 
 
 Antioxidants were observed to have significant priming effects in increasing 
transfection efficiency and transgene expression.  Resveratrol is a natural phenol, 
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specifically a stilbenoid, with antioxidant properties that can be found in the skin of 
grapes [102].  There was toxicity associated with 50 μM and 5 μM resveratrol priming, 
with 50 μM killing most cells in the well, however 5 μM toxicity was moderate, and 
resulted in one of the highest overall increases to normalized EGFP expression observed 
in the entire screening process, with a 3-fold increase in EGFP expression.  Piceid is a 
glucoside modification of resveratrol, which is also found naturally in plants.  This 
modification seems to blunt the effect of the priming increase on transfection compared 
to resveratrol, while also causing less toxicity.  Like antibiotics, antioxidants affect 
mitochondria, however in a manner that generally protects or improves their function 
[102]. Resveratrol has also been shown to rescue mitochondrial dysfunction and 
modulate autophagy [103], which could have beneficial effects in the context of cytotoxic 
effects of PEI transfection [39].  Rescued mitochondria could regain normal function, 
while autophagy inhibits apoptosis. 
 
 
Figure 2.22. Flavonoid priming fold changes in transgene expression 
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 Flavonoids are another class of plant-derived phenols [104], though the effects of 
their priming upon transfection varied.  Epigallocatechin gallate for instance, highly 
knocked down transfection at both 5 and 50uM concentrations, yet Ipriflavone and Icariin 
both increased transfection.  If these antioxidants are each modulating transfection 
through mitochondria and oxidative stress response [105], the variation in priming effects 
may indicate that the cellular stress response to transfection can be modulated to increase 
or decrease transfection, depending on the specific interactions with mitochondrial and 
oxidative pathways each compound affects. 
 
2.4.3 GABAA allosteric modulators increase PEI transfection of HEK293T cells 
 
 
Figure 2.23. GABAA modulator priming fold changes in transgene expression 
 
Diazepam and stiripentol both demonstrated a priming increase to transfection at 
both 5 and 50uM.  These drugs are both positive allosteric modulators of the GABAA 
receptor found in neurons, however, they are thought to act on different subunits [106, 
107]. The priming effects seen of these GABAA modulators is curious because 
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neurotransmitter receptors are not typically expressed in most cell types.  An interesting 
possibility is that the proposed adrenal cortex origin of HEK293T cells [108] could imply 
that the GABAA receptor, or at least some of the subunits, may be expressed in their cell 
membrane.  Another possibility is that these drugs are acting on the translocator protein, 
also known as the peripheral benzodiazepine receptor, which is found in the membranes 
of mitochondria, and thought to be involved in steroidogenesis, and redox regulation of 
mitophagy [109, 110].  The latter would make sense in the context of priming the cellular 
stress response to transfection that many of the other hits also imply. 
 
2.4.4 Glucocorticoids increase PEI transfection of HEK293T cells 
 
 
Figure 2.24. Glucocorticoid priming fold changes in transgene expression 
 
 Another group of compounds that was identified by the screen to prime and 
increase transfection were glucocorticoids.  Glucocorticoids are hormones which are 
involved in the body’s stress response, activating the glucocorticoid receptor, which 
translocates to the nucleus and acts as a transcription factor.  It has been demonstrated 
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previously in our lab that priming with glucocorticoids in human mesenchymal stem cells 
increases transfection many fold [49]  
The mechanism is not yet known, though it has been shown by preliminary data 
to be associated with cytosolic glucocorticoid receptor, not the membrane glucocorticoid 
receptor.  Activated glucocorticoid receptors may play a role in priming transfection by 
assisting internalization, nuclear transport, and nuclear import of transfection complexes.  
Alternatively, or perhaps in conjunction, the glucocorticoid priming effects may be 
occurring through modulation of mitochondria and autophagy [111, 112], which would 
align with the possible mechanisms of priming other drug classes showed in the screen in 
relation to the cellular stress response to transfection. 
 
2.4.5 Preliminary Screen Verification 
 
Six of the compounds identified by the screen to have priming effects at 5 μM 
were re-tested for validation in triplicate.  The validation experiment was seeded in a 48-
well plate format, and LUC/BCA assays were used to assess transfection.  Three of these 
compounds had been shown by the screen to enhance transfection, with the other three 
shown by the screen to decrease transfection.   
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Figure 2.25. Triplicate LUC/BCA verification of screen hits 
 
From Figure 2.25, the relative levels of luciferase expression for all six 
compounds, normalized by total protein, indicate that the screening process was able to 
identify compounds that have priming effects on transfection.  The yellow bars indicate 
compounds that increased transfection in the screen, and did the same in this validation 
experiment.  The red bars indicate compounds that had decreased transfection in the 
screen.  In this validation experiment, one of the compounds, epigallocatechin gallate, 
was consistent in knocking down transfection, but the other two compounds instead 
showed an apparent increase in transfection within this validation experiment.   
This result is not necessarily a conflict with the screen data, as luciferase 
expression normalized by total protein does not providing the exact same information as 
EGFP intensity measurements normalized by cell count.  The relative transgene protein 
expression levels should be consistent, but the observed differences could be attributable 
to the different method of normalization, if total protein does not always necessarily 
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correlate with total cell count.  The differences could also simply be due to differences in 
well plate format or un-optimized scaling of the various reagents to the larger well area. 
The discrepancy should be investigated to prove whether the priming effects 
observed of those drugs in the screen are real or a false positive.  Some number of false 
positives are inevitable in high throughput screening.  In fact, it is encouraging that four 
of the six identified in the screen to have priming effects, repeated those effects in the 
verification experiment.  A visual representation is given in Figure 2.26 below, which 
shows the differences in EGFP expression in the priming conditions versus the 
transfected vehicle control.  EGCG consistently demonstrated consistency in knocking 
down transfection, while resveratrol was one of the highest performers in the screen, and 
continued to demonstrate high fold change enhancement of PEI transfection.  
Corticosterone also repeated its enhancement of transfection, confirming its result in the 
screen and also providing additional evidence of the reliability of glucocorticoid priming.  
Noticeable in many of the compounds which had high fold change increases to 
transfection were increased toxicity.  The toxicity may be due to the priming compound’s 
toxic effects, or amplification of the toxic effects of PEI, though another possibility is that 
the production of mass quantities of EGFP transgene is causing cytotoxicity through 
either EGFP toxicity [113] or the energy burden of transgene overexpression.  An option 
to test whether the toxicity is related to overexpression is to use a weaker promoter in the 
pDNA sequence and/or less efficient formulation of PEI. 
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Figure 2.26 LUC/BCA verification images showing relative EGFP expression 
in cells primed with resveratrol, corticosterone, and EGCG versus transfected 
vehicle control treatment. 
 
 
2.5 Conclusion 
 
Altogether, the literature review of grouped screen hit compounds implies that 
many of the priming effects may be due to modulation of the cellular oxidative stress 
response to PEI transfection, in particular mitochondrial dysfunction.  PEI has been 
shown to have cytotoxic effects through its accumulation in and interaction with 
mitochondrial membranes [39].  Damage to mitochondria has been implicated in the 
intracellular inflammatory and immune response [114, 115], and PEI has also been 
shown to be an effective adjuvant to stimulate an immune response [116].   
Typical cellular responses to mitochondrial damage are autophagy/mitophagy, 
apoptosis, and necrosis.  Apoptosis and autophagy are mutually inhibitory [117], with 
apoptosis leading to cell death, while autophagy possibly serves a protective role in PEI 
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cytotoxicity [118].  It seems plausible that antioxidants, in general, rescue the cell from 
PEI-induced mitochondrial dysfunction, thus improving transfection, while priming with 
other compounds, like antibiotics, may themselves induce mitochondrial dysfunction, or 
perhaps promote autophagy or apoptosis.   
Gene expression profiling has shown that there is differential expression in the 
cellular oxidative stress response associated with successfully versus unsuccessfully PEI 
transfected cells, through ATF3, IREB2 and other gene pathways [50-52]. The screen 
data from this thesis support this claim, and suggest that modulating the cellular stress 
response by priming with clinically approved compounds prior to PEI transfection can 
have significant effects on overall transfection efficiency and transgene expression in 
vitro. 
Not only did the screen identify dozens of compounds that modulate PEI 
transfection, the corroboration of the screen results with other work in the literature 
indicates that the screen was successful in reinforcing and improving understanding of 
pathways with which the total cellular response to nonviral gene delivery can be 
modulated to improve transfection, and suggests specific classes of clinically approved 
compounds which may be immediately useful in vitro and in vivo. 
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CHAPTER 3 
Further Processing and Verification of the High Throughput Screen, and 
Investigation of Priming Mechanisms Involving Mitochondria and Cellular Stress 
 
3.1 Introduction 
 
 With the plenty of information gained from the screen, future work can proceed in 
many directions, from completing the initial hit selection process from the data of six of 
the ten NCC plates, to further analyzing the data already collected in the screen to extract 
more information.  A follow up high throughput LUC/BCA screen can be performed on 
the lysate in cold storage, possibly with ATP quantification, to assess the initial imaging 
screen’s performance, providing complementary transgene expression data, as well as an 
additional cellular stress response measure.  The screen image set can be further analyzed 
by incorporating more sophisticated imaging algorithms to extract additional relevant 
data.  In the initial hit selection process, only EGFP expression and efficiency fold 
changes and Hoechst count fold changes were considered as criteria, so Hoechst intensity 
and Resazurin fold changes should also be analyzed in concert with the EGFP data to 
understand the cell state at the time transfection was assessed, specifically cell viability 
and extent of apoptotic and necrotic cell death. All of the screen measurements should be 
incorporated into a more sophisticated hit selection strategy that incorporates the screen 
data, literature information on candidate compound mechanisms and activity, and 
previously identified differential gene expression profiles of PEI transfection in 
HEK293T cells [50-52] into a network analysis approach  to select priming candidates by 
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a method that is sensitive to trends and patterns in the data, rather than relying on 
inspection to catch the obvious trends.   Additionally, the compounds which have been 
identified by the screen thus far should be investigated in detail and incorporated as 
priming adjuvants in new and effective gene delivery strategies. 
 
3.2 Assessing screen performance 
 
Preliminary analysis of the screen thus far shows that it has been successful in 
achieving its purpose by identifying 38 compounds, and nine different drug classes, for 
further investigation into priming of transfection (See Tables A.1-A.4 in Appendix A, 
and Table 2.1 in Chapter 2).  However, a true assessment of screen performance and the 
hit selection methods used remains to be completed.  In automated high throughput 
screens of siRNA, a primary screen is generally conducted without replicates and 
followed up with a confirmatory screen of at least triplicate [119]. In comparison, the 
transfection priming screen of this thesis could be thought of as a primary screen in 
duplicate.  The addition of a duplicate to the primary screen should provide more 
confidence in preliminary examination of the screened compounds, but it is not enough 
replicates for the screen to be considered confirmatory [119]. 
The initial approach was to perform LUC/BCA validation of a few compounds of 
interest that could then be immediately investigated if confirmed.  Preliminary validation 
of this type was performed that was generally confirmatory of the original hits, with two 
of the six compounds showing an opposite effect from screen observation (Figure 2.25 in 
Chapter 2), though as discussed previously, these differences could possibly be explained 
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by an un-optimized switch from 96 well to 48 well format or the differences between 
normalization by total cell count and by total protein.  Even if all six compounds had 
confirmed their effects observed in the screen, six compounds out of 725 is not a 
sufficient sample size to assess the screen’s performance, and four out of six is actually 
encouraging in providing evidence that the screen results are real. 
The most complete way to assess the performance of this initial primary duplicate 
screen would be to perform a total confirmatory screen, amounting to a repeat of the 
screen in triplicate.  However, the cost in materials and manual effort involved in the 
initial screen make it unlikely that a total confirmatory screen will be performed without 
automation of the liquid handling and imaging processes.  An alternative would be to do 
a partial confirmatory screen, that is, repeat the screen in triplicate for a subset of the 
entire collection, possibly a plate or small number of plates in the collection, from which 
the initial screen’s performance could be estimated. 
 
3.3 High throughput LUC/BCA assays and ATP quantification of screen lysate for 
imaging screen validation and complementary measures of transfection 
 
An alternative to a total or partial confirmatory repeat screen could be high 
throughput assays of LUC/BCA performed on the frozen lysate of the initial screen.  This 
alternative measure of transfection could be used to validate the initial fluorescence 
imaging method.  Compared to the initial LUC/BCA validation experiment (Chapter 
2.4.5), there should be no issue with normalization or plate format, as the counts from the 
initial screen can be used for normalization and there is no need to repeat the seeding, 
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priming, and transfection processes, as the lysate is ready to test.  The BCA assay will 
also incorporate total protein into the dataset as a new relevant measure of the cell 
response to transfection, a complementary measure of toxicity and/or viability, or an 
alternative measure for normalization of the screen data.   
The screen was conducted with a plasmid encoding an EGFPLuc fusion protein, 
so LUC/BCA assays can be performed on the lysate, which has been stored at -80 °C.  
High-throughput luciferase assay reagent kits are offered by several manufacturers, 
which use a “glow” reagent formulation that reacts with luciferase for sustained 
luminescence, allowing multiple wells to be measured over an extended period of time 
without steep drop off in photons emitted due to long reaction times, which would cause 
erroneous variation in apparent luciferase between wells [120]. 
Given access to a plate luminometer, the primary barrier to performing these 
assays would be reagent cost.  To perform LUC/BCA assays on the 40 plates in the 
screen, at a luciferase assay reagent cost of at least fifty cents per sample (Steady-LUC 
Firefly HTS Assay Kit, Biotium), material costs would be at least $3,000.  With 
“homemade” luciferase assay reagent, the total cost could be brought down to about 
$1,000 total [120]. Also, a potential advantage of processing the screen lysate is the 
opportunity to incorporate an ATP quantification assay along with the LUC/BCA 
measurements.  This is convenient because ATP quantification assays rely on the same 
luminescent reaction that is used to quantify luciferase [121], as shown in Figure 3.1 
below. 
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Figure 3.1. Firefly luciferase catalyzes the luminescent reaction of d-luciferin [122]. 
 
 In luciferase quantification, the kinetics of the luminescent reaction depend on the 
concentration of firefly luciferase present in the lysate [120, 121].  In ATP quantification 
by this same reaction, d-luciferin and luciferase are mixed at specific concentrations, and 
a standard curve of luminescence versus ATP concentration is measured.  The relative 
luminescence of lysate samples treated with the same concentrations of d-luciferin and 
luciferase can then be compared to the standard curve to determine ATP concentration 
present in the lysate [120, 121].  ATP quantification can easily be multiplexed into the 
LUC/BCA assay, simply requiring more of the same reagents used in LUC 
quantification, as well as a portion of the sample lysate.  Besides additional cost, the only 
barrier to ATP quantification would be the ability of the ATP, LUC, and BCA assays to 
perform accurately with smaller portions of the screen lysate sample volume 
Measurement of ATP would be complementary to the Resazurin measurements 
already acquired in the screen.  Resazurin assays measure the overall redox state of the 
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cell, while measuring ATP quantifies the available energy currency of the cell [123].  
Both are markers for cell viability, however, they are related but not equivalent measures, 
and analysis of both together might reveal subtle details of the manner in which 
metabolic pathways are disturbed by PEI transfection cytotoxicity and possibly rescued 
by some of the identified priming compounds (antioxidants, GABAA modulators, 
glucocorticoids, etc., see Chapter 2.4) 
 
3.4 Normalized Hoechst intensity measurements as a marker for cell cycle and cell 
death 
 
 For the screen presented in Chapter 2, the Hoechst stain was used for total cell 
enumeration, as both a measure of toxicity and means of normalization, but more 
information can be extracted from the screen data through the normalized Hoechst 
intensity measurements.  While mean image intensity of a Hoechst stain image is 
primarily dependent on cell count, normalizing Hoechst intensity by cell count will result 
in a metric that reveals permeability of the cell and nuclear membranes as well as the 
packing and integrity of chromatin [124, 125].  These parameters are markers for cell 
cycle state, as well as apoptosis and necrosis [126].  Cell cycle and cell death pathways 
can be associated with transfection efficiency, transgene expression, and metabolic 
viability, and contribute to a more complete understanding of priming effects on 
transfection through modulation of the total cellular response. 
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3.5 Phase contrast image analysis as a measurement of cell morphology 
 
The screen image set can be further analyzed by incorporating more sophisticated 
image processing algorithms to extract more relevant data.  As mentioned previously 
(Chapter 2.3.6), there is potential for the screen’s phase contrast images to be processed 
by algorithms that can normalize the differences in illumination and shadow, after which, 
total cell area can be calculated by thresholding algorithms.  Normalization of cell area 
by total cell count would provide a metric of average cell morphology, specifically cell 
spreading, which could imply information of cell motility and extent of cell adhesion to 
the well bottom substrate.  Interpretation of cell spreading as a measurement of cell 
motility and adhesion could allow cell spreading to serve as a proxy measurement of cell 
membrane features related to environmental sensing and phagocytosis, such as actin 
podia features and membrane ruffling, which preliminary work in our lab has indicated 
may play a role in transfection complex internalization (data not shown). 
 
3.6 Image segmentation to enable determination of EGFP expression of 
subpopulations sorted by Hoechst stain 
 
 The image processing used in the screen described in Chapter 2 has been simple 
in its approach.  Total image mean fluorescence intensity was processed to average 
fluorescence intensity per cell when normalized by cell count.  A more nuanced approach 
would be to actually measure fluorescence intensity for each cell, allowing for population 
distributions to be determined.  This approach would be enabled by cell segmentation, 
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which is simply identification of boundaries for each cell in an image.  Cell segmentation 
image processing algorithms are fairly complex and were outside the initial scope of this 
screen.  Such algorithms achieve segmentation by fitting contours to image features, and 
can be implemented by custom code, freeware such as ImageJ and CellProfiler, or 
commercial image cytometry software. 
For this screen, the phase image of each well would be the source image from 
which the segmentation algorithm determines cell boundaries, so the previously 
described preprocessing normalization of illumination and shadows would be necessary.  
Segmented cell outlines can then be applied to the EGFP fluorescence images, from 
which EGFP intensities of each cell could be measured and used to create a histogram 
which captures the number of cells that are expressing EGFP at each observed intensity.  
From these observed probability distributions of both EGFP and Hoechst intensities, 2D 
histograms (scatter plots) could be created for each screened compound that allow for 
association of EGFP expression with different subpopulations of cells sorted by Hoechst 
stain.  This type of information would be a more powerful data set from which to 
interpret priming effects of the screened compounds on PEI transfection. 
 
3.7 Interpreting the screen data by network analysis 
 
From the initial screen, and potential follow-up LUC/BCA/ATP screen, for each 
compound within the drug college, there will be a collection of measurements related to 
the cellular response to priming and transfection, as well as measurements of transfection 
efficiency and transgene expression.  Beyond providing obvious candidates for 
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immediate investigation as priming agents, the data can be analyzed as a whole to inform 
our general understanding of transfection and the cellular response to transfection.  For 
instance, a relationship between transfection priming of certain compound classes and 
mitochondrial dysfunction modulation is suggested by preliminary examination of the 
data.  A rigorous network analysis of the data set should support (or deny) this 
correlation, while other relationships may become apparent.  The network analysis should 
incorporate normalized transfection measurements (EGFP, Luc), normalized cellular 
response measurements (Hoechst, Resazurin, BCA, ATP, Phase area), keyword 
annotations of known targets of the screened compounds (receptors, pathways, 
organelles, etc.), and the gene expression profiles of successfully and unsuccessfully 
transfected cell populations.  The software of choice for analysis of high throughput 
screen data is the R/Bioconductor statistical computing language and environment, which 
has HTS packages generally tailored for siRNA HTS and DNA microarray data.  
R/Bioconductor is the software which was used in previous FACS/microarray 
experiments in our lab, which we would like to incorporate into the network analysis for 
hit selection in any case, so R/Bioconductor network analysis and high throughput 
screening packages would be a good place to start for this bioinformatics approach to hit 
selection. 
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3.8 Verification and investigation of priming mechanisms that involve modulation of 
mitochondrial dysfunction and cellular stress response. 
 
 The majority of compounds identified as hits thus far from the screen seem to 
possibly be modulating the mitochondrial dysfunction that is caused by PEI toxicity.  To 
verify the priming effects of these compounds, priming with these compounds should be 
tested at a variety of concentrations, over a variety of time points pre- and post-
transfection, to determine the breadth of the priming effect and optimum priming 
condition.  The timing information will be important in determining the window of time 
cells can be primed by these compounds to have their effect on mitochondrial 
dysfunction in a way that improves or decreases transfection.  Optimized timing and 
dosing parameters can be determined for each compound for use in the experiments 
which follow that attempt to decipher the specific mechanisms of the observed priming 
effects. 
 There are methods that mitochondria can be assayed directly.  Mitochondrial 
respirometry can be performed on isolated mitochondria to measure changes in oxygen 
flux due to treatment of the priming agent [127].  Certain probes are also now able to 
measure oxygen consumption in cultured cells (XF Extracellular Flux Analyzer, Seahorse 
Bioscience) [128].  Also membrane potential can be monitored to examine how redox 
potential across the mitochondrial membrane can change in response to PEI and priming 
compounds.  ATP is also a good indicator of mitochondrial viability, which can be 
measured by luminescence [121]. 
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 Another approach would be to mimic the gene expression profiling microarray 
experiments performed in our lab previously[50-52], in terms of sorting the transfected 
and un-transfected cell populations and assaying the subpopulations for differential gene 
expression, in this case by qRT-PCR of genes that had been previously identified to be 
related to cellular stress response, such as RAP1A, ATF3, IREB2, as well as genes whose 
expression are known specific markers for mitochondrial dysfunction, autophagy, 
apoptosis, and necrosis [39, 117, 129]. 
In addition to the qRT-PCR measures of gene expression, the transfected and 
untransfected subpopulations should also be run through subcellular fractionation by 
gradient centrifugation in order to quantify relative amounts of PEI and plasmid in the 
various cell compartments.  In subcellular fractionation, cells are gently lysed and 
centrifuged through a density gradient to separate organelles by density.  With optimized 
subcellular fractionation protocols, nuclei, mitochondria, lysosomes, and cytoplasmic 
fractions can be isolated.  These separated fractions can then be measured for both 
plasmid count and PEI concentration, with the plasmid count quantified by qRT-PCR, 
and the PEI likely pre-labeled by conjugation to a fluorophore for fluorescence 
quantification.  These localization measurements in the various cellular compartments 
should also be determined at various time points after priming and transfection for an 
estimate of the transport mechanisms that are taking place for both the plasmid and PEI.  
The change in PEI localization within the various compartments over time should be 
informative, especially the amount of PEI which is found in mitochondria, in terms of the 
mitochondrial dysfunction modulation priming hypothesis.   
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Pull down methods and/or high resolution FRET imaging should also be used to 
identify specific protein/protein and protein/DNA interactions that may be affecting the 
behavior and interactions of complexes and cell machinery in response to priming.  
siRNA could be useful for identifying such proteomic interactions as well by knocking 
down specific genes/proteins and observing the resulting impact on priming.  siRNA may 
provide more precision in modulating a gene pathway than chemical inhibitors/activators. 
From these experiments, screen hits should be verified by correlation of transfection fold 
changes, cell viability measures, and specific changes in gene expression related to cell 
stress response, autophagy, apoptosis, and necrosis, relative amounts of plasmid and PEI 
in the various compartments of the cell, as well as specific protein/protein and 
protein/DNA interactions, all in the context of successfully versus unsuccessfully 
transfected cell populations. These experiments will hopefully illuminate the specific 
mechanisms by which priming can rescue or mitigate mitochondrial dysfunction due to 
PEI toxicity. 
 
3.9 Final thoughts 
 
Through high throughput screening of the NIH Clinical Collection, priming 
compounds which impact nonviral gene delivery have been identified which reinforce 
and improve our understanding of transfection and provide new tools for improving the 
efficiency of gene transfer.  With partial, preliminary hit selection from the collected 
data, dozens of clinically approved priming compounds have potentially been identified.  
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The remainder of the data should be assessed, possibly with more sophisticated image 
processing techniques and hit selection approaches.   
Grouping of the preliminary hits has implicated modulation of the cellular stress 
response and mitochondrial dysfunction as important aspects of PEI transfection, so the 
specific mechanisms by which these drug classes modulate mitochondria to affect 
transfection should be investigated in detail, which will require a detailed understanding 
of mitochondrial physiology, cellular stress pathways, and interplay between autophagy, 
apoptotic, and necrotic cell death.  The mechanistic relationships between PEI 
transfection and different priming compounds on all of these processes will require 
extensive literature review and experimentation. The apparent success of this study in 
identifying clinical compounds that prime nonviral gene delivery could also warrant a 
comprehensive automated screen of a larger compound library in combination with 
different cell types, carriers, and nucleic acids, to confirm priming as a generally 
applicable tool for nonviral gene delivery.   
Overall, the identification of clinically approved priming compounds by this 
screen is promising for the potential of their future implementation as adjuvants of 
nonviral gene delivery in vivo and eventually in clinical gene therapy applications.  Even 
the clinical compounds that were found to decrease transfection are also possibly 
important to understand as potential contraindications for patients who are depending on 
expression of a therapeutic gene through nonviral gene delivery. 
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APPENDIX A: Tables listing NCC Compounds that prime transfection 
 FC: Fold-change 
 EGFP Max/Min FC: Maximum or minimum fold change in EGFP expression or 
transfection efficiency, plate reader or image measurement, normalized by total 
cell count or transfected cell count. 
 Bolded drugs were selected as hits from these lists by fold change, toxicity, and 
drug grouping based on literature annotations of each drugs known mechanisms 
of action. 
 
Table A.1 NCC Compounds that increase transfection at 50 μm 
 
EGFP Max FC Hoechst Count FC Drug Name Grouped Drug Class 
1.35 1.05 NICORANDIL 
 
1.37 0.68 DIAZEPAM GABA 
1.32 0.68 ALOSETRON 
 
1.23 1.02 NORNICOTINE 
 
1.67 0.7 EPIRIZOLE NSAID 
1.32 0.65 VARDENAFIL 
 
1.77 0.72 STIRIPENTOL GABA 
1.4 0.74 TOCAINIDE 
 
1.47 0.76 BENACTYZINE 
 
1.55 0.6 2-PYRIDYLETHYLAMINE 
 
1.41 0.78 ICARIIN FLAVONOID 
1.63 0.68 CETRAXATE 
 
1.69 0.49 SR 57227A 
 
1.95 0.81 KETOROLAC NSAID 
1.42 0.59 PANTOPRAZOLE PROTON PUMP INHIBITOR 
2.16 0.39 LOFEXIDINE 
 
2.26 0.55 ZARDAVERINE 
 
1.73 0.43 ISRADIPINE 
 
2.27 0.4 INDOMETACIN NSAID 
1.72 0.46 DIHYDREXIDINE 
 
2.22 0.32 CLONIDINE 
 
2.32 0.52 FLUCYTOSINE ANTIFUNGAL 
2.09 0.48 ROSIGLITAZONE 
 
3.63 0.55 TRANILAST 
 
2.63 0.69 PICEID STILBENOID 
1.75 0.49 RUFLOXACIN 
 
2.11 0.44 FENOLDOPAM 
 
2.07 0.51 NATEGLINIDE 
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Table A.2 NCC Compounds that increase transfection at 5 μM  
 
EGFP Max FC Hoechst Count FC Drug Name Grouped Drug Class 
1.39 0.71 VORICONAZOLE ANTIFUNGAL 
1.30 0.84 DIAZEPAM GABA 
1.53 0.74 MEGESTROL ACETATE 
 
1.57 0.65 ITRACONAZOLE ANTIFUNGAL 
1.39 0.83 PIROXICAM NSAID 
1.50 0.65 TRYPTOLINE 
 
1.31 0.63 AM251 
 
1.61 0.48 HALOPERIDOL 
 
1.31 0.62 STIRIPENTOL GABA 
1.36 0.60 OXYPHENONIUM BROMIDE 
 
1.60 0.60 METHOXYTRYPTAMINE 
 
1.43 0.67 MESALAZINE NSAID 
1.44 0.71 SELEGILINE 
 
1.59 0.56 ITOPRIDE 
 
1.30 0.55 QUETIAPINE 
 
1.24 0.66 CYCLOSERINE 
 
1.55 0.60 DEXCHLORPHENIRAMINE ANTIHISTAMINE 
1.21 0.63 LEVORPHANOL 
 
1.33 0.86 DEXBROMPHENIRAMINE ANTIHISTAMINE 
1.55 0.60 LOFEXIDINE 
 
1.54 0.96 CALCITRIOL 
 
1.59 0.72 OXAPROZIN NSAID 
1.53 0.73 REMACEMIDE 
 
1.71 0.54 LOFEPRAMINE 
 
1.52 0.67 TROXIPIDE 
 
1.87 0.49 MEDROXYPROGESTERONE HORMONE 
1.52 0.69 OMEPRAZOLE PROTON PUMP INHIBITOR 
1.72 0.60 CYPROHEPTADINE ANTIHISTAMINE 
1.49 0.70 BECLOMETASONE GLUCOCORTICOID 
1.52 0.86 ROLITETRACYCLINE ANTIBIOTIC 
1.51 0.65 CORTICOSTERONE GLUCOCORTICOID 
2.01 0.45 DESOXIMETASONE GLUCOCORTICOID 
1.57 0.64 2-CHLOROADENOSINE 
 
3.04 0.55 RESVERATROL STILBENOID 
1.78 0.54 MEPIVACAINE 
 
4.28 0.36 IPRIFLAVONE FLAVONOID 
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Table A.3 NCC Compounds that decrease transfection at 50 μM  
EGFP Min FC Hoechst Count FC Drug Name Grouped Drug Class 
0.36 1.67 HYPEROSIDE FLAVONOID 
0.80 1.14 PARECOXIB NSAID 
0.74 1.16 VORICONAZOLE 
 
0.81 1.02 PAZUFLOXACIN ANTIBIOTIC 
0.83 1.09 BUPROPION 
 
0.63 1.24 TOSUFLOXACIN ANTIBIOTIC 
0.71 1.28 CEFACLOR ANTIBIOTIC 
0.61 1.15 CLARITHROMYCIN ANTIBIOTIC 
0.75 1.35 RUTIN FLAVONOID 
0.57 0.83 SKF 83566 
 
0.63 0.49 ETOMOXIR 
 
0.74 0.61 TICLOPIDINE 
 
0.75 0.93 TACRINE 
 
0.00 0.80 
EPIGALLOCATECHIN 
GALLATE 
FLAVONOID 
0.03 1.34 CEFDINIR ANTIBIOTIC 
0.02 1.45 CEFIXIME ANTIBIOTIC 
0.15 1.10 TAXIFOLIN FLAVONOID 
0.06 1.42 ROLITETRACYCLINE ANTIBIOTIC 
 
Table A.4 NCC Compounds that decrease transfection at 5 μM  
EGFP Min FC Hoechst Count FC Drug Name Grouped Drug Class 
0.58 0.95 PRAVASTATIN 
 
0.89 0.93 LAMOTRIGINE 
 
0.94 0.92 TOSUFLOXACIN ANTIBIOTIC 
0.68 0.69 DIPHENOXYLATE 
 
0.93 0.89 TERBINAFINE ANTIFUNGAL 
0.91 0.90 CLARITHROMYCIN ANTIBIOTIC 
0.85 0.94 SDM25N 
 
0.87 0.96 LOXAPINE 
 
0.89 0.90 NAPROXEN NSAID 
0.86 0.94 MALTOL 
 
0.08 1.37 
EPIGALLOCATECHIN 
GALLATE 
FLAVANOID 
0.82 0.90 TRIFLUOPERAZINE 
 
0.78 0.89 NALBUPHINE 
 
0.61 1.36 CEFIXIME ANTIBIOTIC 
0.63 1.36 ISOQUERCETIN FLAVONOID 
0.77 0.76 5-(NONYLOXY)TRYPTAMINE 
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APPENDIX B: ImageJ macros used for image processing 
 
Image intensity and local maxima detection macro: 
 
start=1; 
imagesperwell=3; 
end=288; 
path="C:\\Users\\anguyen2\\Desktop\\AN-15-40\\10\\5uM\\2\\"; 
i=1; 
count=0; 
 
for(x=start+1; x<=end; x=x+3) 
{ 
//gfp images 
  open(path+"image"+x+".tif"); 
  run("Measure"); 
  run("Enhance Local Contrast (CLAHE)", "blocksize=127 histogram=256 
maximum=3 mask=*None* fast_(less_accurate)"); 
  run("Subtract Background...", "rolling=10"); 
  run("Find Maxima...", "noise=10 output=Count"); 
  selectWindow("image"+x+".tif"); 
  close(); 
} 
 
for(x=start+2; x<=end; x=x+3) 
{ 
//hoechst images 
  open(path+"image"+x+".tif"); 
  run("Measure");   
  run("Subtract Background...", "rolling=10"); 
  run("Find Maxima...", "noise=10 output=Count"); 
  selectWindow("image"+x+".tif"); 
  close(); 
} 
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Plate montage creation macro: 
 
 
 
start=1; 
imagesperwell=3; 
end=288; 
path="C:\\Users\\anguyen2\\Desktop\\AN-15-40\\10\\5uM\\2\\"; 
i=1; 
count=0; 
 
 
//phase 
for(x=start; x<=end; x=x+3) 
{ 
 open(path+"image"+x+".tif"); 
} 
 
run("Images to Stack", "name=Stack title=[] use keep"); 
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1 
border=10 font=12"); 
 
for(x=start; x<=end; x=x+3) 
{ 
 selectWindow("image"+x+".tif"); 
 close(); 
} 
 
selectWindow("Montage"); 
run("Rotate 90 Degrees Left"); 
run("Flip Vertically"); 
 
waitForUser; 
 
//gfp 
for(x=start+1; x<=end; x=x+3) 
{ 
 open(path+"image"+x+".tif"); 
} 
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run("Images to Stack", "name=Stack title=[] use keep"); 
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1 
border=10 font=12"); 
 
for(x=start+1; x<=end; x=x+3) 
{ 
 selectWindow("image"+x+".tif"); 
 close(); 
} 
 
selectWindow("Montage"); 
run("Rotate 90 Degrees Left"); 
run("Flip Vertically"); 
 
waitForUser; 
 
//hoechst 
for(x=start+2; x<=end; x=x+3) 
{ 
 open(path+"image"+x+".tif"); 
} 
 
run("Images to Stack", "name=Stack title=[] use keep"); 
run("Make Montage...", "columns=8 rows=12 scale=1 first=1 last=96 increment=1 
border=10 font=12"); 
 
for(x=start+2; x<=end; x=x+3) 
{ 
 selectWindow("image"+x+".tif"); 
 close(); 
} 
 
selectWindow("Montage"); 
run("Rotate 90 Degrees Left"); 
run("Flip Vertically"); 
 
 
